0001103795 2025-01-01 2025-12-31 0001103795 2025-06-30 0001103795 2026-03-27 0001103795 2025-10-01 2025-12-31 0001103795 2025-12-31 0001103795 2024-12-31 0001103795 us-gaap:ConvertibleNotesPayableMember 2025-12-31 0001103795 us-gaap:ConvertibleNotesPayableMember 2024-12-31 0001103795 2024-01-01 2024-12-31 0001103795 us-gaap:CommonStockMember 2023-12-31 0001103795 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001103795 us-gaap:RetainedEarningsMember 2023-12-31 0001103795 2023-12-31 0001103795 us-gaap:CommonStockMember 2024-12-31 0001103795 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001103795 us-gaap:RetainedEarningsMember 2024-12-31 0001103795 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001103795 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001103795 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001103795 us-gaap:CommonStockMember 2025-01-01 2025-12-31 0001103795 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-12-31 0001103795 us-gaap:RetainedEarningsMember 2025-01-01 2025-12-31 0001103795 us-gaap:CommonStockMember 2025-12-31 0001103795 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001103795 us-gaap:RetainedEarningsMember 2025-12-31 0001103795 us-gaap:SubsequentEventMember 2026-01-01 2026-02-28 0001103795 qsep:PatentCostsMember 2025-01-01 2025-12-31 0001103795 qsep:PatentCostsMember 2024-01-01 2024-12-31 0001103795 qsep:StockOptionsMember 2025-01-01 2025-12-31 0001103795 qsep:StockOptionsMember 2024-01-01 2024-12-31 0001103795 qsep:WarrantsMember 2025-01-01 2025-12-31 0001103795 qsep:WarrantsMember 2024-01-01 2024-12-31 0001103795 qsep:ConvertibleNotesMember 2025-01-01 2025-12-31 0001103795 qsep:ConvertibleNotesMember 2024-01-01 2024-12-31 0001103795 us-gaap:OfficeEquipmentMember 2025-12-31 0001103795 us-gaap:OfficeEquipmentMember 2024-12-31 0001103795 us-gaap:FurnitureAndFixturesMember 2025-12-31 0001103795 us-gaap:FurnitureAndFixturesMember 2024-12-31 0001103795 qsep:TestingEquipmentMember 2025-12-31 0001103795 qsep:TestingEquipmentMember 2024-12-31 0001103795 us-gaap:LeaseholdImprovementsMember 2025-12-31 0001103795 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001103795 qsep:ConvertibleNotesMember 2023-12-31 0001103795 qsep:ConvertibleNotesMember 2024-01-01 2024-12-31 0001103795 qsep:ConvertibleNotesMember 2024-12-31 0001103795 us-gaap:WarrantMember qsep:ConvertibleNotesMember 2024-01-01 2024-12-31 0001103795 us-gaap:WarrantMember qsep:ConvertibleNotesMember 2024-12-31 0001103795 qsep:ConvertibleNotesMember 2025-01-01 2025-12-31 0001103795 qsep:ConvertibleNotesMember 2025-12-31 0001103795 us-gaap:WarrantMember qsep:ConvertibleNotesMember 2025-01-01 2025-12-31 0001103795 us-gaap:WarrantMember qsep:ConvertibleNotesMember 2025-12-31 0001103795 us-gaap:ConvertibleNotesPayableMember 2023-12-31 0001103795 us-gaap:ConvertibleNotesPayableMember 2024-01-01 2024-12-31 0001103795 us-gaap:ConvertibleNotesPayableMember 2025-01-01 2025-12-31 0001103795 qsep:DebtDiscountMember 2023-12-31 0001103795 qsep:DebtDiscountMember 2024-01-01 2024-12-31 0001103795 qsep:DebtDiscountMember qsep:OriginalIssueDiscountMember 2024-12-31 0001103795 qsep:DebtDiscountMember qsep:DiscountConvertedMember 2024-01-01 2024-12-31 0001103795 qsep:DebtDiscountMember 2024-12-31 0001103795 qsep:DebtDiscountMember 2025-01-01 2025-12-31 0001103795 qsep:DebtDiscountMember qsep:OriginalIssueDiscountMember 2025-12-31 0001103795 qsep:DebtDiscountMember qsep:DiscountConvertedMember 2025-01-01 2025-12-31 0001103795 qsep:DebtDiscountMember 2025-12-31 0001103795 qsep:PPPLoanMember 2020-06-01 2020-06-30 0001103795 qsep:PPPLoanMember 2023-12-31 0001103795 qsep:PPPLoanMember 2024-01-01 2024-12-31 0001103795 qsep:PPPLoanMember 2024-12-31 0001103795 qsep:PPPLoanMember 2025-01-01 2025-12-31 0001103795 qsep:LicenseAgreementsMember 2025-12-31 0001103795 qsep:LicenseAgreementsMember 2024-12-31 0001103795 2025-07-31 0001103795 qsep:LicenseAgreementsMember 2025-01-01 2025-12-31 0001103795 qsep:LicenseAgreementsMember 2024-01-01 2024-12-31 0001103795 qsep:LicenseAgreementsMember 2025-01-01 2025-12-31 0001103795 qsep:LicenseAgreementsMember 2024-01-01 2024-12-31 0001103795 qsep:AOTPrototypesMember 2025-01-01 2025-12-31 0001103795 qsep:AOTPrototypesMember 2024-01-01 2024-12-31 0001103795 us-gaap:DomesticCountryMember 2025-01-01 2025-12-31 0001103795 us-gaap:DomesticCountryMember 2024-01-01 2024-12-31 0001103795 us-gaap:CommonStockMember 2025-01-01 2025-12-31 0001103795 us-gaap:ConvertibleNotesPayableMember 2025-01-01 2025-12-31 0001103795 us-gaap:ConvertibleNotesPayableMember 2025-12-31 0001103795 srt:MinimumMember us-gaap:ConvertibleNotesPayableMember 2025-01-01 2025-12-31 0001103795 srt:MaximumMember us-gaap:ConvertibleNotesPayableMember 2025-01-01 2025-12-31 0001103795 qsep:ExerciseOfOptionsAndWarrantsMember 2025-01-01 2025-12-31 0001103795 srt:MinimumMember qsep:ExerciseOfOptionsAndWarrantsMember 2025-01-01 2025-12-31 0001103795 srt:MaximumMember qsep:ExerciseOfOptionsAndWarrantsMember 2025-01-01 2025-12-31 0001103795 qsep:CashlessExerciseOfWarrantsMember 2025-01-01 2025-12-31 0001103795 srt:MinimumMember qsep:CashlessExerciseOfWarrantsMember 2025-01-01 2025-12-31 0001103795 srt:MaximumMember qsep:CashlessExerciseOfWarrantsMember 2025-01-01 2025-12-31 0001103795 srt:MinimumMember us-gaap:CommonStockMember 2025-12-31 0001103795 srt:MaximumMember us-gaap:CommonStockMember 2025-12-31 0001103795 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001103795 us-gaap:ConvertibleNotesPayableMember 2024-01-01 2024-12-31 0001103795 us-gaap:ConvertibleNotesPayableMember 2024-12-31 0001103795 srt:MinimumMember us-gaap:ConvertibleNotesPayableMember 2024-01-01 2024-12-31 0001103795 srt:MaximumMember us-gaap:ConvertibleNotesPayableMember 2024-01-01 2024-12-31 0001103795 qsep:ExerciseOfWarrantsMember 2024-01-01 2024-12-31 0001103795 srt:MinimumMember qsep:ExerciseOfWarrantsMember 2024-01-01 2024-12-31 0001103795 srt:MaximumMember qsep:ExerciseOfWarrantsMember 2024-01-01 2024-12-31 0001103795 qsep:CashlessExerciseOfWarrantsMember 2024-01-01 2024-12-31 0001103795 srt:MinimumMember qsep:CashlessExerciseOfWarrantsMember 2024-01-01 2024-12-31 0001103795 srt:MaximumMember qsep:CashlessExerciseOfWarrantsMember 2024-01-01 2024-12-31 0001103795 us-gaap:CommonStockMember 2024-12-31 0001103795 us-gaap:StockOptionMember 2023-12-31 0001103795 us-gaap:StockOptionMember 2024-01-01 2024-12-31 0001103795 us-gaap:StockOptionMember 2024-12-31 0001103795 us-gaap:StockOptionMember 2025-01-01 2025-12-31 0001103795 us-gaap:StockOptionMember 2025-12-31 0001103795 us-gaap:StockOptionMember qsep:OptionPrice1Member 2025-12-31 0001103795 us-gaap:StockOptionMember qsep:OptionPrice1Member 2025-01-01 2025-12-31 0001103795 us-gaap:StockOptionMember qsep:OptionPrice2Member 2025-12-31 0001103795 us-gaap:StockOptionMember qsep:OptionPrice2Member 2025-01-01 2025-12-31 0001103795 qsep:MembersOfTheBoardOfDirectorsMember us-gaap:StockOptionMember 2025-01-01 2025-01-31 0001103795 qsep:MembersOfTheBoardOfDirectorsMember us-gaap:StockOptionMember 2025-02-01 2025-02-28 0001103795 qsep:MembersOfTheBoardOfDirectorsMember qsep:CecilBondKyteMember us-gaap:StockOptionMember 2025-01-01 2025-01-31 0001103795 qsep:MembersOfTheBoardOfDirectorsMember qsep:CecilBondKyteMember us-gaap:StockOptionMember 2025-02-01 2025-02-28 0001103795 qsep:MembersOfTheBoardOfDirectorsMember us-gaap:StockOptionMember qsep:Price02Member 2025-12-31 0001103795 qsep:MembersOfTheBoardOfDirectorsMember us-gaap:StockOptionMember qsep:Price04Member 2025-12-31 0001103795 qsep:MembersOfTheBoardOfDirectorsMember us-gaap:StockOptionMember qsep:Price06Member 2025-12-31 0001103795 qsep:MembersOfTheBoardOfDirectorsMember us-gaap:StockOptionMember qsep:Price08Member 2025-12-31 0001103795 qsep:MembersOfTheBoardOfDirectorsMember us-gaap:StockOptionMember qsep:Price15Member 2025-12-31 0001103795 qsep:MembersOfTheBoardOfDirectorsMember us-gaap:StockOptionMember 2025-01-01 2025-12-31 0001103795 qsep:MembersOfTheBoardOfDirectorsMember us-gaap:StockOptionMember 2025-12-31 0001103795 qsep:CecilBondKyteMember us-gaap:StockOptionMember 2025-01-01 2025-01-31 0001103795 qsep:CecilBondKyteMember us-gaap:StockOptionMember 2025-01-31 0001103795 qsep:CecilBondKyteMember us-gaap:StockOptionMember 2025-01-01 2025-12-31 0001103795 qsep:CorporateSecretaryMember us-gaap:StockOptionMember 2025-03-01 2025-03-31 0001103795 qsep:CorporateSecretaryMember us-gaap:StockOptionMember 2025-03-31 0001103795 qsep:CorporateSecretaryMember us-gaap:StockOptionMember 2025-01-01 2025-12-31 0001103795 us-gaap:StockOptionMember qsep:IssuedForServicesMember 2025-01-01 2025-12-31 0001103795 us-gaap:StockOptionMember qsep:IssuedForServicesMember 2025-12-31 0001103795 srt:MinimumMember us-gaap:StockOptionMember qsep:IssuedForServicesMember 2025-01-01 2025-12-31 0001103795 srt:MaximumMember us-gaap:StockOptionMember qsep:IssuedForServicesMember 2025-01-01 2025-12-31 0001103795 us-gaap:WarrantMember 2025-12-31 0001103795 us-gaap:WarrantMember 2025-01-01 2025-12-31 0001103795 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2026-01-31 0001103795 us-gaap:WarrantMember us-gaap:ConvertibleDebtMember 2025-01-01 2025-12-31 0001103795 us-gaap:WarrantMember us-gaap:ConvertibleDebtMember 2025-12-31 0001103795 us-gaap:WarrantMember qsep:ConsultingAgreementMember 2025-01-01 2025-12-31 0001103795 srt:MinimumMember us-gaap:WarrantMember qsep:ConsultingAgreementMember 2025-12-31 0001103795 srt:MaximumMember us-gaap:WarrantMember qsep:ConsultingAgreementMember 2025-12-31 0001103795 us-gaap:WarrantMember qsep:WarrantsIssuedForConsultantsAndInvestorsMember 2025-01-01 2025-12-31 0001103795 srt:MinimumMember us-gaap:WarrantMember qsep:WarrantsIssuedForConsultantsAndInvestorsMember 2025-01-01 2025-12-31 0001103795 srt:MaximumMember us-gaap:WarrantMember qsep:WarrantsIssuedForConsultantsAndInvestorsMember 2025-01-01 2025-12-31 0001103795 us-gaap:WarrantMember us-gaap:ConvertibleDebtMember 2024-01-01 2024-12-31 0001103795 srt:MinimumMember us-gaap:WarrantMember us-gaap:ConvertibleDebtMember 2024-12-31 0001103795 srt:MaximumMember us-gaap:WarrantMember us-gaap:ConvertibleDebtMember 2024-12-31 0001103795 us-gaap:WarrantMember qsep:ConsultingAgreementMember 2024-01-01 2024-12-31 0001103795 srt:MinimumMember us-gaap:WarrantMember qsep:ConsultingAgreementMember 2024-12-31 0001103795 srt:MaximumMember us-gaap:WarrantMember qsep:ConsultingAgreementMember 2024-12-31 0001103795 srt:MinimumMember us-gaap:WarrantMember qsep:ConsultingAgreementMember 2024-01-01 2024-12-31 0001103795 srt:MaximumMember us-gaap:WarrantMember qsep:ConsultingAgreementMember 2024-01-01 2024-12-31 0001103795 us-gaap:WarrantMember 2023-12-31 0001103795 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001103795 us-gaap:WarrantMember 2024-12-31 0001103795 us-gaap:WarrantMember qsep:Warrant1Member 2025-12-31 0001103795 us-gaap:WarrantMember qsep:Price1Member 2025-01-01 2025-12-31 0001103795 us-gaap:WarrantMember qsep:Warrant2Member 2025-12-31 0001103795 us-gaap:WarrantMember qsep:Price2Member 2025-01-01 2025-12-31 0001103795 qsep:CEOAndCFOMember 2024-07-07 2024-12-31 0001103795 qsep:CEOAndCFOMember qsep:EmploymentAgreementMember 2025-12-31 0001103795 qsep:CEOAndCFOMember qsep:EmploymentAgreementMember 2025-01-02 0001103795 qsep:CEOAndCFOMember qsep:EmploymentAgreementMember 2025-01-01 2025-01-31 0001103795 qsep:CEOAndCFOMember qsep:ExecutionOfEquityFinancingMember qsep:EmploymentAgreementMember 2025-12-31 0001103795 qsep:CEOAndCFOMember qsep:RestrictedCommonStockMember qsep:EmploymentAgreementMember 2025-01-01 2025-12-31 0001103795 qsep:CEOAndCFOMember qsep:RestrictedCommonStockMember qsep:EmploymentAgreementMember 2025-12-31 0001103795 qsep:CEOAndCFOMember qsep:RestrictedCommonStock2Member qsep:EmploymentAgreementMember 2025-01-01 2025-12-31 0001103795 qsep:CEOAndCFOMember qsep:RestrictedCommonStock2Member qsep:EmploymentAgreementMember 2025-12-31 0001103795 qsep:MembersOfTheBoardOfDirectorsMember srt:ChiefFinancialOfficerMember us-gaap:StockOptionMember 2025-01-01 2025-12-31 0001103795 qsep:CEOAndCFOMember 2025-01-01 2025-12-31 0001103795 qsep:CompensationAgreementsMember 2025-12-31 0001103795 qsep:CompensationAgreementsMember 2024-12-31 0001103795 qsep:SignificantAgreementMember 2025-01-01 2025-12-31 0001103795 qsep:SignificantAgreementMember 2025-12-31 0001103795 us-gaap:OperatingSegmentsMember 2025-01-01 2025-12-31 0001103795 us-gaap:OperatingSegmentsMember 2024-01-01 2024-12-31 iso4217:USD shares iso4217:USD shares pure qsep:Integer false 2025 FY 0001103795

10-K true 2025-12-31 --12-31 false 0-29185 QS ENERGY, INC. NV 52-2088326 23902 FM 2978 Tomball TX 77375 775 300-7647 Common Stock, $0.001 par value No No Yes Yes Non-accelerated Filer true false false false false 100504000 550617942 Risk Management and StrategyWe are subject to cyber and other security threats, including potential threats to gain access to our confidential, private, and proprietary information. However, we have not established at this time any policies, standards, processes, or practices, including Board oversight, to assess, identify, and manage material risks from cybersecurity threats. (See “Risk Factors,” in Item 1A, above.) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20250101__20251231_zHyHEkALW9c4">As of the date of this report, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250101__20251231_zM80BYLsdJZc">we are not aware of any cybersecurity threats that would materially affect, or would reasonably likely materially affect our business or our efforts to commercialize our AOT technology. We can provide no assurances that there will not be cyberattacks in the future or that any such attacks would not materially affect our business or efforts to commercialize our AOT technology. As of the date of this report, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250101__20251231_zM80BYLsdJZc">we are not aware of any cybersecurity threats that would materially affect, or would reasonably likely materially affect our business or our efforts to commercialize our AOT technology. false false false false false true 572 Weinberg & Company, P.A. Los Angeles, California

6000

150000

49000

11000

55000

161000

3000

55000

164000

3167000

2433000

1416000

881000

16000

133000

1116000

2339000

1351000

2524000

24000

5934000

5862000

5934000

5862000

0.001

750000000

543350596

428424880

543351

428428

136182649

121173575

-142605000

-127300000

-5879000

-5698000

55000

164000

13312000

1385000

1611000

191000

-14923000

-1576000

389000

358000

7000

-15305000

-1934000

-0.03

-0.00

499682276

404977565

392586471

392587

119729413

-125366000

-5244000

32341748 32342 303658 336000

782000

1063332 1063 50937 52000 433329 433 17567 18000 152000 152000

2000000

2000

138000

140000

-1934000

428424880

428425

121173575

-127300000

-5698000

428424880

428425

121173575

-127300000

-5698000

65523469 65524 2312476 2378000

1430000

36802254 36802 1566198 1603000 2049993 2050 101950 104000

7407000

511000

9050000

9050

1441950

1451000

1500000

1500

238500

240000

-15305000

543350596

543351

136182649

-142605000

-5879000

-15305000

-1934000

7407000 152000

511000

1451000

140000

240000

204000

98000

146000

213000

3000

1000

38000

-1000

639000

-73000

734000

235000

-4008000

-1167000

-0

2000

-2000

2285000

1230000

1603000

52000

24000

33000

3864000

1249000

-144000

80000

150000

70000

6000

150000

1600

3803000 1034000 104000 18000 1430000 782000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 34px">1.</td> <td style="text-align: justify">Business and Summary of Significant Accounting Policies</td></tr> </table> QS Energy, Inc. (“QS Energy”, “Company”) was incorporated on February 18, 1998, as a Nevada Corporation under the name Mandalay Capital Corporation. The Company changed its name to Save the World Air, Inc. on February 11, 1999. Effective August 11, 2015, the Company changed its name to QS Energy, Inc. QS Energy develops and seeks to commercialize energy efficiency technologies that assist in meeting increasing global energy demands, improving the economics of oil transport, and reducing greenhouse gas emissions. The Company’s intellectual properties include a portfolio of domestic and international patents, a substantial portion of which have been developed in conjunction with and exclusively licensed from Temple University of Philadelphia, PA (“Temple”). QS Energy’s primary technology is called Applied Oil Technology (AOT), a commercial-grade crude oil pipeline transportation flow-assurance product. Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, during the twelve-months ended December 31, 2025, the Company incurred a net loss of $15,305,000, used cash in operations of $4,008,000 and as of December 31, 2025, had a stockholders’ deficit of $5,879,000. In addition, as of December 31, 2025, 51 notes payable with an aggregate balance of $1,116,000 and certain obligations to a former officer are past due. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. At December 31, 2025, the Company had cash on hand in the amount of $6,000. In January through February 2026, the Company issued 4,718,188 shares of its common stock upon the exercise of warrants for proceeds of $472,000. The AOT product is still in development and testing and has transitioned from laboratory testing to initial demonstration and continued testing in advance of our goal of seeking commercial acceptance and adoption by the upstream and midstream pipeline marketplace. QS Energy’s efforts in the foregoing regard have been substantially hampered by a lack of capital. The Company should be able to continue its efforts to commercialize its AOT product during 2026 only if sufficient capital is raised to do so. The Company can provide no assurances in its ability to raise the capital needed to continue efforts in 2026, or that any such capital will be available to it on acceptable terms and conditions. Management is currently seeking additional funds, primarily through the issuance of debt and equity securities for cash to operate our business, including without limitation the expenses it will incur in connection with the license agreements with Temple; costs associated with product development and commercialization of the AOT technologies; costs to manufacture and ship the products; costs to design and implement an effective system of internal controls and disclosure controls and procedures; costs of maintaining our status as a public company by filing periodic reports with the SEC and costs required to protect our intellectual property. In addition, as discussed below, the Company has substantial contractual commitments, including without limitation salaries to our executive officers pursuant to employment agreements, and certain payments to a former officer and consulting fees, during the remainder of 2026 and beyond. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders in case of equity financing. Inflation Macroeconomic factors such as inflation, rising interest rates, governmental responses there to and possible recession caused thereby also add significant uncertainty to our operations and possible effects to the amount and type of financing available to the Company in the future. <p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zSgaFymDc1Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Basis of Presentation The accompanying consolidated financial statements and related notes include activities of the Company and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The consolidated financial statements include the accounts of QS Energy Inc. and its wholly owned subsidiaries, QS Energy Pool, Inc. and STWA Asia Pte. Limited. Intercompany transactions and balances have been eliminated in consolidation. Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include those related to assumptions used in valuing equity instruments issued for financing and services, the realizability of deferred tax assets and the related valuation allowance, accruals for potential liabilities, and assumptions used in the determination of the Company’s liquidity. Actual results could differ from these estimates. Revenue Recognition Under its business plan, the Company anticipates the leasing of its primary technology. The Company will recognize lease revenue ratably over the life of the lease upon commencement of the lease. Revenue on future product sales will be recognized in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. Cash Cash consists of demand deposits with banks. The Company holds no cash equivalents as of December 31, 2025 and 2024, respectively. The Company maintains its cash with domestic financial institutions. At times, cash balances may exceed federally insured limits of $250,000 per depositor at each financial institution. The Company believes that no significant concentration of credit risk exists with respect to these cash balances because of its assessment of the creditworthiness and financial viability of the financial institutions. Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of the assets, generally ranging from three to ten years. Expenditures for major renewals and improvements that extend the useful lives of property and equipment are capitalized. Expenditures for repairs and maintenance are charged to expense as incurred. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the lease term. <p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zcvVSrHLML5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Impairment of Long-lived Assets Our long-lived assets, such as property and equipment, are reviewed for impairment at least annually, or when events and circumstances indicate that depreciable or amortizable long-lived assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. When specific assets are determined to be unrecoverable, the cost basis of the asset is reduced to reflect the current value. Based upon management’s annual review, no impairments were recorded for the years ended December 31, 2025 and 2024. Leases The Company accounts for its leases in accordance with the guidance of ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments (see Note 3). Income Taxes The Company uses an asset and liability method for accounting for income taxes. The Company recognizes deferred tax assets and liabilities to reflect the estimated future tax effects, calculated at anticipated future tax rates, of future deductible or taxable amounts attributable to events that have been recognized on a cumulative basis in the financial statements. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Research and Development Costs Research and development expenses relate primarily to the development, design, testing of preproduction prototypes and models, compensation, and consulting fees, and are expensed as incurred. Total research and development costs recorded during the years ended December 31, 2025 and 2024, amounted to $1,611,000 and $191,000, respectively. Patent Costs Patent costs consist of patent-related legal and filing fees. Due to the uncertainty associated with the successful development of our AOT product, all patent costs are expensed as incurred. During the years ended December 31, 2025 and 2024, patent costs were $5,000 and $34,000, respectively, and were included as part of operating expenses in the accompanying consolidated statements of operations. Stock-Based Compensation The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for stock-based payments to officers, directors, employees, and consultants by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s financial statements over the vesting period of the awards. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of the Company's stock options and warrants grant is estimated using the Black-Scholes Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or warrants, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes Option Pricing model could materially affect compensation expense recorded in future periods. Accounting for Warrants The Company evaluates all of its financial instruments, including issued warrants, to determine if such instruments are liability classified, pursuant to ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) or derivatives or contain features that qualify as embedded derivatives pursuant to ASC 815, Derivatives and Hedging (“ASC 815”). The classification of instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Liability classified warrants are measured at fair value at inception and at each reporting date, with changes in fair value recognized in the statements of operations in the period of change. Fair Value of Financial Instruments Accounting standards require certain assets and liabilities to be reported at fair value in the financial statements and provide a framework for establishing that fair value. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The framework for determining fair value is based on a hierarchy that prioritizes the inputs and valuation techniques used to measure fair value: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The Company is required to use observable market data if such data is available without undue cost and effort. The carrying amounts for cash, accounts payable, accrued expenses and convertible notes payable approximate their fair value due to the short-term nature of such instruments. Loss per Common Share Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the loss of the Company. In computing diluted loss per share, the treasury stock method assumes that outstanding options and warrants are exercised, and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. For the years ended December 31, 2025 and 2024, the dilutive impact of outstanding stock options of <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zY1HuFATxaOd" title="Antidilutive shares">69,015,001 shares and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zObqhJwMLQnc" title="Antidilutive shares">25,294,103 shares; outstanding warrants of <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zEHOEc2UHjDd" title="Antidilutive shares">45,622,728 shares and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zBuEbOIEXTxd" title="Antidilutive shares">44,044,009 shares; and notes convertible into approximately <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zVkylJMjDbJi" title="Antidilutive shares">16,408,334 and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zyEs7kFTmLbl" title="Antidilutive shares">48,304,534 shares of our common stock, respectively, have been excluded because their impact on the loss per share is anti-dilutive. <p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zVgBQLLqrKm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Segment Information The Company’s Chief Executive Officer (”CEO”) is our chief operating decision maker (“CODM”) and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single reportable segment composed of the consolidated financial results of QS Energy, Inc. (see Note 12). Recent Accounting Pronouncements In November 2024, the FASB issued ASU No. 2024-03 “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” This ASU requires public business entities to disclose, for interim and annual reporting periods, additional information about certain income statement expense categories. The requirements are effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027. Entities are permitted to apply either the prospective or retrospective transition methods. The Company is currently evaluating the impact that the adoption of this ASU will have on its consolidated financial statements. The Company’s management has evaluated all other the recently issued, but not yet effective, accounting standards and guidance that have been issued or proposed by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission through the filing date of these financial statements and does not believe the future adoption of any such pronouncements will have a material effect on the Company’s financial position and results of operations.

Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, during the twelve-months ended December 31, 2025, the Company incurred a net loss of $15,305,000, used cash in operations of $4,008,000 and as of December 31, 2025, had a stockholders’ deficit of $5,879,000. In addition, as of December 31, 2025, 51 notes payable with an aggregate balance of $1,116,000 and certain obligations to a former officer are past due. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. At December 31, 2025, the Company had cash on hand in the amount of $6,000. In January through February 2026, the Company issued 4,718,188 shares of its common stock upon the exercise of warrants for proceeds of $472,000. The AOT product is still in development and testing and has transitioned from laboratory testing to initial demonstration and continued testing in advance of our goal of seeking commercial acceptance and adoption by the upstream and midstream pipeline marketplace. QS Energy’s efforts in the foregoing regard have been substantially hampered by a lack of capital. The Company should be able to continue its efforts to commercialize its AOT product during 2026 only if sufficient capital is raised to do so. The Company can provide no assurances in its ability to raise the capital needed to continue efforts in 2026, or that any such capital will be available to it on acceptable terms and conditions. Management is currently seeking additional funds, primarily through the issuance of debt and equity securities for cash to operate our business, including without limitation the expenses it will incur in connection with the license agreements with Temple; costs associated with product development and commercialization of the AOT technologies; costs to manufacture and ship the products; costs to design and implement an effective system of internal controls and disclosure controls and procedures; costs of maintaining our status as a public company by filing periodic reports with the SEC and costs required to protect our intellectual property. In addition, as discussed below, the Company has substantial contractual commitments, including without limitation salaries to our executive officers pursuant to employment agreements, and certain payments to a former officer and consulting fees, during the remainder of 2026 and beyond. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders in case of equity financing.

-15305000

-4008000

-5879000

1116000

6000

4718188

472000

Inflation Macroeconomic factors such as inflation, rising interest rates, governmental responses there to and possible recession caused thereby also add significant uncertainty to our operations and possible effects to the amount and type of financing available to the Company in the future.

<p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zSgaFymDc1Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Basis of Presentation The accompanying consolidated financial statements and related notes include activities of the Company and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The consolidated financial statements include the accounts of QS Energy Inc. and its wholly owned subsidiaries, QS Energy Pool, Inc. and STWA Asia Pte. Limited. Intercompany transactions and balances have been eliminated in consolidation.

Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include those related to assumptions used in valuing equity instruments issued for financing and services, the realizability of deferred tax assets and the related valuation allowance, accruals for potential liabilities, and assumptions used in the determination of the Company’s liquidity. Actual results could differ from these estimates.

Revenue Recognition Under its business plan, the Company anticipates the leasing of its primary technology. The Company will recognize lease revenue ratably over the life of the lease upon commencement of the lease. Revenue on future product sales will be recognized in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers.

Cash Cash consists of demand deposits with banks. The Company holds no cash equivalents as of December 31, 2025 and 2024, respectively. The Company maintains its cash with domestic financial institutions. At times, cash balances may exceed federally insured limits of $250,000 per depositor at each financial institution. The Company believes that no significant concentration of credit risk exists with respect to these cash balances because of its assessment of the creditworthiness and financial viability of the financial institutions.

Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of the assets, generally ranging from three to ten years. Expenditures for major renewals and improvements that extend the useful lives of property and equipment are capitalized. Expenditures for repairs and maintenance are charged to expense as incurred. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the lease term.

<p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zcvVSrHLML5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Impairment of Long-lived Assets Our long-lived assets, such as property and equipment, are reviewed for impairment at least annually, or when events and circumstances indicate that depreciable or amortizable long-lived assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. When specific assets are determined to be unrecoverable, the cost basis of the asset is reduced to reflect the current value. Based upon management’s annual review, no impairments were recorded for the years ended December 31, 2025 and 2024.

Leases The Company accounts for its leases in accordance with the guidance of ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments (see Note 3).

Income Taxes The Company uses an asset and liability method for accounting for income taxes. The Company recognizes deferred tax assets and liabilities to reflect the estimated future tax effects, calculated at anticipated future tax rates, of future deductible or taxable amounts attributable to events that have been recognized on a cumulative basis in the financial statements. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized.

Research and Development Costs Research and development expenses relate primarily to the development, design, testing of preproduction prototypes and models, compensation, and consulting fees, and are expensed as incurred. Total research and development costs recorded during the years ended December 31, 2025 and 2024, amounted to $1,611,000 and $191,000, respectively.

1611000

191000

Patent Costs Patent costs consist of patent-related legal and filing fees. Due to the uncertainty associated with the successful development of our AOT product, all patent costs are expensed as incurred. During the years ended December 31, 2025 and 2024, patent costs were $5,000 and $34,000, respectively, and were included as part of operating expenses in the accompanying consolidated statements of operations.

5000

34000

Stock-Based Compensation The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for stock-based payments to officers, directors, employees, and consultants by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s financial statements over the vesting period of the awards. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of the Company's stock options and warrants grant is estimated using the Black-Scholes Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or warrants, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes Option Pricing model could materially affect compensation expense recorded in future periods.

Accounting for Warrants The Company evaluates all of its financial instruments, including issued warrants, to determine if such instruments are liability classified, pursuant to ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) or derivatives or contain features that qualify as embedded derivatives pursuant to ASC 815, Derivatives and Hedging (“ASC 815”). The classification of instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Liability classified warrants are measured at fair value at inception and at each reporting date, with changes in fair value recognized in the statements of operations in the period of change.

Fair Value of Financial Instruments Accounting standards require certain assets and liabilities to be reported at fair value in the financial statements and provide a framework for establishing that fair value. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The framework for determining fair value is based on a hierarchy that prioritizes the inputs and valuation techniques used to measure fair value: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The Company is required to use observable market data if such data is available without undue cost and effort. The carrying amounts for cash, accounts payable, accrued expenses and convertible notes payable approximate their fair value due to the short-term nature of such instruments.

Loss per Common Share Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the loss of the Company. In computing diluted loss per share, the treasury stock method assumes that outstanding options and warrants are exercised, and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. For the years ended December 31, 2025 and 2024, the dilutive impact of outstanding stock options of <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zY1HuFATxaOd" title="Antidilutive shares">69,015,001 shares and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zObqhJwMLQnc" title="Antidilutive shares">25,294,103 shares; outstanding warrants of <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zEHOEc2UHjDd" title="Antidilutive shares">45,622,728 shares and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zBuEbOIEXTxd" title="Antidilutive shares">44,044,009 shares; and notes convertible into approximately <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zVkylJMjDbJi" title="Antidilutive shares">16,408,334 and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zyEs7kFTmLbl" title="Antidilutive shares">48,304,534 shares of our common stock, respectively, have been excluded because their impact on the loss per share is anti-dilutive.

69015001

25294103

45622728

44044009

16408334

48304534

<p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zVgBQLLqrKm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Segment Information The Company’s Chief Executive Officer (”CEO”) is our chief operating decision maker (“CODM”) and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single reportable segment composed of the consolidated financial results of QS Energy, Inc. (see Note 12).

Recent Accounting Pronouncements In November 2024, the FASB issued ASU No. 2024-03 “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” This ASU requires public business entities to disclose, for interim and annual reporting periods, additional information about certain income statement expense categories. The requirements are effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027. Entities are permitted to apply either the prospective or retrospective transition methods. The Company is currently evaluating the impact that the adoption of this ASU will have on its consolidated financial statements. The Company’s management has evaluated all other the recently issued, but not yet effective, accounting standards and guidance that have been issued or proposed by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission through the filing date of these financial statements and does not believe the future adoption of any such pronouncements will have a material effect on the Company’s financial position and results of operations.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 34px">2.</td> <td style="text-align: justify">Property and Equipment</td></tr> </table> At December 31, 2025 and 2024, property and equipment consists of the following: <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--PropertyPlantAndEquipmentTextBlock_zbzUSMOP499g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of property and equipment</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Office equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zUTyonQQXACk" style="width: 13%; text-align: right" title="Property and equipment, gross">37,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zFkhz6d7pcai" style="width: 13%; text-align: right" title="Property and equipment, gross">37,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Furniture and fixtures</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zSRuOSzXoQ2a" style="text-align: right" title="Property and equipment, gross">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z2Fscq2hTBx7" style="text-align: right" title="Property and equipment, gross">5,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Testing equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TestingEquipmentMember_zAlP5ET26NTe" style="text-align: right" title="Property and equipment, gross">37,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TestingEquipmentMember_zqFq5Jn3k6t7" style="text-align: right" title="Property and equipment, gross">37,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Leasehold Improvements</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zOEAfBMIHigj" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross">25,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zAfisMzIuI63" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross">25,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Subtotal</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20251231_zDOctUhRi23i" style="text-align: right" title="Property and equipment, gross">104,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20241231_zUnEKJDMoFLi" style="text-align: right" title="Property and equipment, gross">104,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20251231_z8dDQyOvcxUd" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated depreciation">(104,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20241231_zq1gPrXTjnU8" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated depreciation">(101,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_d0_c20251231_zgBhfoWEwAl3" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20241231_zQv4S1oRNNWj" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">3,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Depreciation expense for the years ended December 31, 2025 and 2024 was $3,000 and $1,000, respectively.

<table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--PropertyPlantAndEquipmentTextBlock_zbzUSMOP499g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of property and equipment</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Office equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zUTyonQQXACk" style="width: 13%; text-align: right" title="Property and equipment, gross">37,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zFkhz6d7pcai" style="width: 13%; text-align: right" title="Property and equipment, gross">37,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Furniture and fixtures</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zSRuOSzXoQ2a" style="text-align: right" title="Property and equipment, gross">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z2Fscq2hTBx7" style="text-align: right" title="Property and equipment, gross">5,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Testing equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TestingEquipmentMember_zAlP5ET26NTe" style="text-align: right" title="Property and equipment, gross">37,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TestingEquipmentMember_zqFq5Jn3k6t7" style="text-align: right" title="Property and equipment, gross">37,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Leasehold Improvements</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zOEAfBMIHigj" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross">25,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zAfisMzIuI63" style="border-bottom: Black 1pt solid; text-align: right" title="Property and equipment, gross">25,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Subtotal</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20251231_zDOctUhRi23i" style="text-align: right" title="Property and equipment, gross">104,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20241231_zUnEKJDMoFLi" style="text-align: right" title="Property and equipment, gross">104,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20251231_z8dDQyOvcxUd" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated depreciation">(104,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20241231_zq1gPrXTjnU8" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated depreciation">(101,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_d0_c20251231_zgBhfoWEwAl3" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20241231_zQv4S1oRNNWj" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">3,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

37000

5000

37000

25000

104000

101000

3000

1000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 34px">3.</td> <td style="text-align: justify">Leases </td></tr> </table> The Company accounts for its leases in accordance with ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Operating lease right-of-use (“ROU”) assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. ROU assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. At December 31, 2025 and 2024, the Company had no long term leases. During the years ended December 31, 2025 and 2024, the Company rented certain spaces on a month-to-month basis, and rent expense was $17,000 and $15,800, respectively.

17000

15800

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 34px">4.</td> <td style="text-align: justify">Convertible Notes Payable</td></tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ConvertibleDebtTableTextBlock_zi4JQpftag8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Notes Payable (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of convertible notes payable</td><td> </td> <td colspan="2" id="xdx_494_20251231_zicJ7ShUp8u9" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49C_20241231_zHRp1NgZ7Gg1" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleDebtCurrent_iI_maCzEzh_zC8tvLgZ7oO9" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Convertible notes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">822,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,651,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InterestPayableCurrent_iI_maCzEzh_zHdgbKrGUpF8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accrued interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">545,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,006,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ConvertibleNotesPayable_iI_znZsbBCbOS6h" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Total outstanding debt, including $1,116,000 and $2,339,000 in default at December 31, 2025 and 2024, respectively</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,367,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,657,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentCarryingAmount_iNI_di_zvn3Dvi0gE4e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Unamortized debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(16,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(133,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayableCurrent_iI_zyu5uejrql0g" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Total outstanding debt, net of unamortized debt discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,351,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,524,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Convertible notes At December 31, 2023, convertible notes payable totaled $1,332,000. During the year ended December 31, 2024, the Company issued convertible promissory notes in the aggregate of $<span id="xdx_90F_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_pp0p0_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember_zXeak0BvzzF4" title="Convertible promissory notes issued">1,353,000 for cash proceeds of $1,230,000, net of OID of $123,000. The notes are unsecured, with a 10% original issue discount, mature in twelve months from issuance, and are convertible into 42,457,348 shares of the Company’s common stock at $0.03 to $0.05 per share. In addition, the Company granted the note holders warrants to purchase <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zX5j5Dbn5Trb" title="Common stock shares for warrants issued">42,457,348 shares of the Company’s common stock with a relative fair value of $<span id="xdx_90E_ecustom--CommonStockSharesForWarrantsIssuedValue_iI_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zQuy71y4Fc7e" title="Warrants issued, value">782,000. The warrants are fully vested and expire one year from the date of issuance. The Company determined the fair value of the warrants by using a Black-Scholes option pricing model, with the following assumptions: expected term of 1.0 year, stock price of $0.05 to $0.12, exercise price of $0.04 to $0.07, volatility of 156% to 174%, risk-free rate of 3.98% to 5.09%, and no forfeiture rate. Also during 2024, convertible notes of $1,034,000, net of unamortized discount of $699,000, were converted into <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember_zRwdncy3O5V9" title="Debt converted, shares issued">32,341,748 shares of common stock. At December 31, 2024, total outstanding convertible notes payable totaled $1,651,000. During the year ended December 31, 2025, the Company issued convertible promissory notes in the aggregate of $<span id="xdx_90B_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_pp0p0_c20250101__20251231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember_zo00OVz50xZj" title="Convertible promissory notes issued">2,515,000 for cash proceeds of $2,285,000, net of original issue discount (“OID”) of $229,000. The notes are unsecured, mature in twelve months from issuance, and are convertible into shares of the Company’s common stock at $0.08 per share. In addition, the Company granted the note holders warrants to purchase <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250101__20251231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zzc9OXeCFg75" title="Common stock shares for warrants issued">31,423,615 shares of the Company’s common stock with a relative value of $<span id="xdx_907_ecustom--CommonStockSharesForWarrantsIssuedValue_iI_c20251231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zkPdabK6v1Cg" title="Warrants issued, value">1,430,000. The warrants are fully vested, and expire one year from the date of issuance. The Company determined the fair value of the warrants by using a Black-Scholes option pricing model, with the following assumptions: expected term of 1.0 year, stock price of $0.16 to $0.20, exercise price of $0.10, volatility of 136% to 160%, risk-free rate of 3.96% to 4.03%, and no forfeiture rate. Also, during the year ended December 31 2025, convertible notes of $3,344,000, net of unamortized discount of $1,572,000, were converted into <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250101__20251231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember_z7YMrUbuG82l" title="Debt converted, shares issued">65,523,469 shares of common stock (see also accrued interest below). At December 31, 2025, total outstanding convertible notes payable totaled $822,000. As of December 31, 2025, convertible notes payable and accrued interest are convertible into approximately 16,408,334 shares of common stock at conversion rates ranging from $0.03 to $0.48 per share. As of December 31, 2025, a total of 51 convertible notes and accrued interest in the aggregate of $1,116,000 have reached maturity and are past due. Accrued interest At December 31, 2023, accrued interest on convertible notes payable totaled $793,000. During the year ended December 31, 2024, accrued interest of $213,000 was recorded. At December 31, 2024, accrued interest on convertible notes payable totaled $1,006,000. During the year ended December 31, 2025, accrued interest of $146,000 was recorded. Also, during the year ended December 31 2025, accrued interest on convertible notes of $<span id="xdx_90F_ecustom--DebtConversionConvertedInterestAmount1_pp0p0_c20250101__20251231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zLgr2qLt1F8e" title="Debt converted, interest converted">607,000 was converted into shares of common stock. At December 31, 2025, accrued interest on convertible notes payable totaled $545,000. Debt discount At December 31, 2023, the unamortized debt discount was $25,000. During the year ended December 31, 2024, debt discount of $905,000 was recorded for the relative fair value of warrants of $<span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsValue_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zDo2uxevKsvc" title="Warrants issued, value">782,000 and OID of $<span id="xdx_90A_ecustom--OriginalIssueDiscount_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--DebtDiscountMember__us-gaap--TransactionTypeAxis__custom--OriginalIssueDiscountMember_zir5p5qBqtV" title="Increase in debt discount">123,000, debt discount amortization of $98,000 was recorded, and $<span id="xdx_907_ecustom--DecreaseInDebtDiscount_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--DebtDiscountMember__us-gaap--TransactionTypeAxis__custom--DiscountConvertedMember_zTBaaAw2zW16" title="Decrease in debt discount">699,000 of debt discount was removed and included in the carrying amount of related convertible notes payable that were converted into shares of common stock. At December 31, 2024, the unamortized debt discount was $133,000. During the year ended December 31, 2025, debt discount of $1,659,000 was recorded for the relative fair value of warrants of $<span id="xdx_90A_ecustom--CommonStockSharesForWarrantsIssuedValue_iI_c20251231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zSQWyeSlwHJh" title="Warrants issued, value">1,430,000 and OID of $<span id="xdx_90C_ecustom--OriginalIssueDiscount_iI_c20251231__us-gaap--DebtInstrumentAxis__custom--DebtDiscountMember__us-gaap--TransactionTypeAxis__custom--OriginalIssueDiscountMember_zn9WjgHTxf3d" title="Increase in debt discount">229,000, debt discount amortization of $204,000 was recorded, and $<span id="xdx_900_ecustom--DecreaseInDebtDiscount_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--DebtDiscountMember__us-gaap--TransactionTypeAxis__custom--DiscountConvertedMember_zhlH3xdDnyh2" title="Decrease in debt discount">1,572,000 of debt discount was removed and included in the carrying amount of related convertible notes payable that were converted into shares of common stock. At December 31, 2025, the unamortized debt discount was $16,000.

<table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ConvertibleDebtTableTextBlock_zi4JQpftag8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Notes Payable (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of convertible notes payable</td><td> </td> <td colspan="2" id="xdx_494_20251231_zicJ7ShUp8u9" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49C_20241231_zHRp1NgZ7Gg1" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleDebtCurrent_iI_maCzEzh_zC8tvLgZ7oO9" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Convertible notes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">822,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,651,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InterestPayableCurrent_iI_maCzEzh_zHdgbKrGUpF8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accrued interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">545,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,006,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ConvertibleNotesPayable_iI_znZsbBCbOS6h" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Total outstanding debt, including $1,116,000 and $2,339,000 in default at December 31, 2025 and 2024, respectively</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,367,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,657,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentCarryingAmount_iNI_di_zvn3Dvi0gE4e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Unamortized debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(16,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(133,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayableCurrent_iI_zyu5uejrql0g" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Total outstanding debt, net of unamortized debt discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,351,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,524,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

822000

1651000

545000

1006000

1116000

2339000

1367000

2657000

16000

133000

1351000

2524000

1332000

1353000

1230000

123000

42457348

782000

1034000

699000

32341748

1651000

2515000

2285000

229000

31423615

1430000

3344000

1572000

65523469

822000

convertible notes payable and accrued interest are convertible into approximately 16,408,334 shares of common stock at conversion rates ranging from $0.03 to $0.48 per share.

1116000

793000

213000

1006000

146000

607000

545000

25000

905000 782000 123000

98000

699000

133000

1659000 1430000 229000

204000

1572000

16000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 34px">5.</td> <td style="text-align: justify">PPP Loan Payable</td></tr> </table> In June 2020, the Company was granted a loan (the “PPP loan”) from Cadence Bank in the aggregate amount of $151,000, pursuant to the Paycheck Protection Program (the “PPP”) under the CARES Act. At December 31, 2023, the balance of the PPP loan was $57,000. During the year ended December 31, 2024, the Company paid $33,000 of principal, and at December 31, 2024, the balance of the PPP loan was $24,000. During the year ended December 31, 2025, the Company paid $24,000 of the principal on the PPP loan, and at December 31, 2025, the PPP loan was paid in full.

151000

57000

33000

24000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 34px">6.</td> <td style="text-align: justify">Research and Development</td></tr> </table> The Company constructs, develops and tests the AOT technology with internal resources and through the assistance of various third-party entities. Costs incurred and expensed include fees such as license fees, purchase of test equipment, viscometers, SCADA systems, computer equipment, direct costs related to AOT equipment manufacture and installation, payroll and other related equipment and various logistical expenses for the purposes of evaluating and testing the Company’s AOT prototypes. Costs incurred for research and development are expensed as incurred. Purchased materials that do not have an alternative future use are also expensed. Furthermore, costs incurred in the construction of prototypes with no certainty of any alternative future use and established commercial uses are also expensed. For the years ended December 31, 2025 and 2024, our research and development expenses were $1,611,000 and $191,000, respectively. Temple University Licensing Agreement-amount past due On August 1, 2011, the Company entered into two Exclusive License Agreements with Temple University (“Temple”). One license agreement covered technology to reduce crude oil viscosity (referred to as the “AOT-1 Agreement”) and the second license agreement covered technology associated with an electric and/or magnetic field assisted fuel injector system (referred to as the “AOT-2 Agreement”, and together the AOT-1 Agreement, the “License Agreements”). The License Agreements provide the Company with exclusive, worldwide rights to Temple’s patents, patent applications, and technical information related to the respective technologies. Pursuant to the original terms of the License Agreements, the Company paid Temple a non-refundable license maintenance fee of $300,000 and agreed to pay (i) annual maintenance fees of $187,500, (ii) royalty fees ranging from 4% to 7% on net sales and extended term net sales, and (iii) 25% of all revenues generated from sublicenses. Effective as of September 26, 2025, the Company and Temple executed Amendment No. 2 to the AOT-1 Agreement and Amendment No. 1 to the AOT-2 Agreement, under which the Company and Temple agreed that total outstanding fees due to Temple through July 31, 2025, were $2,236,000 and $931,000, respectively, for an aggregate amount of $3,167,000 (collectively, the “Outstanding Amounts”). The Outstanding Amounts were required to be paid by October 11, 2025. As of the date of this filing, the Outstanding Amounts have not been paid to Temple. As of December 31, 2025 and December 31, 2024, total unpaid fees due to Temple under the License Agreements amounted to $3,167,000 and $2,433,000, respectively, which are included in accounts payable – license agreements in the accompanying consolidated balance sheets. Under the amended agreements, royalty rates are structured as follows: 7% on the first $20 million of applicable net sales, 6% on sales between $20 million and $40 million, 5% on sales between $40 million and $100 million, and 4% on sales in excess of $100 million. These rates apply both during the initial term of the agreements and throughout the “Extended Term,” defined as a period of at least ten (10) years beginning upon the expiration of the last to expire patent (including continuations, extensions, and foreign counterparts), or upon early termination, whichever occurs earlier. During the Extended Term, royalties remain payable on all extended term net sales, regardless of patent expiration or the existence of valid claims. The amended agreements also clarified that the Company shall retain exclusive rights to any improvements developed solely by the Company during or after the Extended Term, and Temple shall have no ownership interest in such improvements. Notwithstanding this, the Company remains obligated to pay royalties on such sales during the Extended Term. For the years ended December 31, 2025 and 2024, total expenses recognized under the License Agreements amounted to $698,000 and $188,000, respectively, and are included in research and development expenses. In addition, the Company recognized penalty interest on past due balances of $36,000 and $48,000 for the years ended December 31, 2025 and 2024, respectively, which is included in interest and financing expense. No revenues were recognized from these License Agreements during the year ended December 31, 2025 and 2024. AOT Prototypes During the years ended December 31, 2025 and 2024, the Company incurred total expenses of $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20250101__20251231__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--AOTPrototypesMember_zTMtnGt146ak" title="Research and development expenses">913,000 and $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20241231__us-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis__custom--AOTPrototypesMember_zpT6ecUiurA9" title="Research and development expenses">3,000, respectively, in the manufacture and testing of the AOT prototype equipment. These expenses have been reflected as part of Research and Development expenses on the accompanying consolidated statements of operations.

1611000

191000

2236000 931000

3167000

2433000

Under the amended agreements, royalty rates are structured as follows: 7% on the first $20 million of applicable net sales, 6% on sales between $20 million and $40 million, 5% on sales between $40 million and $100 million, and 4% on sales in excess of $100 million. These rates apply both during the initial term of the agreements and throughout the “Extended Term,” defined as a period of at least ten (10) years

698000

188000

36000

48000

913000

3000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">7.</td> <td style="text-align: justify">Income Taxes</td></tr> </table> The Company did not provide for any Federal and State income tax for the years ended December 31, 2025 and 2024 due to the Company’s net losses. A reconciliation of income taxes with the amounts computed at the statutory federal rate follows: <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zR7Qw26OlDWb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Income tax reconciliation)"> <tr style="vertical-align: bottom"> <td>Schedule of reconciliation of income taxes</td><td> </td> <td colspan="2" id="xdx_49F_20250101__20251231_zDsaH0He0kyk" style="text-align: center"> </td><td> </td> <td> </td> <td> </td> <td> </td> <td> </td><td> </td> <td colspan="2" id="xdx_498_20240101__20241231_zlQMV43j3m7g" style="text-align: center"> </td><td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td> <td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td> <td style="text-align: center"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_maITEBzUek_z0rUUBvzS6Mk" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: left">Computed tax provision (benefit) at federal statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(3,193,000</td><td style="width: 1%; text-align: left">)</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 11%">21%</td> <td style="width: 1%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(406,000</td><td style="width: 1%; text-align: left">)</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 11%">21%</td> <td style="width: 1%"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_maITEBzUek_zzkwjzIOXQ7a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,194,600</td><td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20250101__20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zNiwfAOuKDO1">(21%</td> <td style="padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">406,000</td><td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zyw5x2Xlllce">(21%</td> <td style="padding-bottom: 1pt">)</td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_d0_mtITEBzUek_zAgRZWL8yAqc" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"> </td> <td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_d0_c20250101__20251231_zs4buoFbCkF7" style="border-bottom: Black 2.5pt double; text-align: right">–</td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"> </td> <td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_d0_c20240101__20241231_zQ6v56nwx5Cj" style="border-bottom: Black 2.5pt double; text-align: right">–</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> The deferred tax assets and deferred tax liabilities recorded on the balance sheet are as follows: <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zb9MwMb767Qh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Deferred taxes)"> <tr style="vertical-align: bottom"> <td>Schedule of deferred tax assets and deferred tax liabilities</td><td> </td> <td colspan="2" id="xdx_490_20251231_zuQMzZs3zWth" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49D_20241231_ztIRupOVpODg" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Net operating loss carry forwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">13,838,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">12,872,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesDeferredExpense_iNI_di_z5nVes4Q6Eoj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,555,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(32,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxLiabilitiesOther_iI_zcILrMQp8Rr3" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Other temporary differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(270,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(33,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zmUOyjSYVr5b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,013,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,807,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iI_d0_zUzaPURz3BZ6" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Total deferred taxes net of valuation allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of December 31, 2025, the Company had net operating losses available for carry forward for state and federal tax purposes of approximately $66 million expiring through 2045. These carry forward benefits will be subject to annual limitations due to the ownership change limitations imposed by the Internal Revenue Code and similar state provisions. The annual limitation, if imposed, may result in the expiration of net operating losses before utilization. As of December 31, 2025, the Company recorded a valuation allowance of $12,013,000 for its deferred tax assets since the Company believes that such assets did not meet the more likely than not criteria to be recoverable through projected future profitable operations in the foreseeable future. This valuation is based on the federal corporate tax rate of 21%. The Company follow FASB guidance that addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under this guidance, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The FASB also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. As of December 31, 2025 and 2024, the Company does not have a liability for unrecognized tax benefits. The Company files income tax returns in the U.S. federal jurisdiction and the State of Texas. The Company is subject to U.S. federal or state income tax examinations by tax authorities for years after 2022. During the periods open to examination, the Company has net operating loss and tax credit carry forwards for U.S. federal and state tax purposes that have attributes from closed periods. Since these net operating losses and tax credit carry forwards may be utilized in future periods, they remain subject to examination. The Company’s policy is to record interest and penalties on uncertain tax provisions as income tax expense. As of December 31, 2025, the Company has no accrued interest or penalties related to uncertain tax positions. The Company believes that it has not taken any uncertain tax positions that would impact its consolidated financial statements as of December 31, 2025 and 2024.

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zR7Qw26OlDWb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Income tax reconciliation)"> <tr style="vertical-align: bottom"> <td>Schedule of reconciliation of income taxes</td><td> </td> <td colspan="2" id="xdx_49F_20250101__20251231_zDsaH0He0kyk" style="text-align: center"> </td><td> </td> <td> </td> <td> </td> <td> </td> <td> </td><td> </td> <td colspan="2" id="xdx_498_20240101__20241231_zlQMV43j3m7g" style="text-align: center"> </td><td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td> <td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td> <td style="text-align: center"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_maITEBzUek_z0rUUBvzS6Mk" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: left">Computed tax provision (benefit) at federal statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(3,193,000</td><td style="width: 1%; text-align: left">)</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 11%">21%</td> <td style="width: 1%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(406,000</td><td style="width: 1%; text-align: left">)</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 11%">21%</td> <td style="width: 1%"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_maITEBzUek_zzkwjzIOXQ7a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,194,600</td><td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20250101__20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zNiwfAOuKDO1">(21%</td> <td style="padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">406,000</td><td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zyw5x2Xlllce">(21%</td> <td style="padding-bottom: 1pt">)</td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_d0_mtITEBzUek_zAgRZWL8yAqc" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"> </td> <td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_d0_c20250101__20251231_zs4buoFbCkF7" style="border-bottom: Black 2.5pt double; text-align: right">–</td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"> </td> <td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_d0_c20240101__20241231_zQ6v56nwx5Cj" style="border-bottom: Black 2.5pt double; text-align: right">–</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

-3193000

0.21

-406000

0.21

3194600

-0.21

406000

-0.21

1600

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zb9MwMb767Qh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Deferred taxes)"> <tr style="vertical-align: bottom"> <td>Schedule of deferred tax assets and deferred tax liabilities</td><td> </td> <td colspan="2" id="xdx_490_20251231_zuQMzZs3zWth" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49D_20241231_ztIRupOVpODg" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Net operating loss carry forwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">13,838,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">12,872,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesDeferredExpense_iNI_di_z5nVes4Q6Eoj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,555,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(32,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxLiabilitiesOther_iI_zcILrMQp8Rr3" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Other temporary differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(270,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(33,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zmUOyjSYVr5b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,013,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,807,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iI_d0_zUzaPURz3BZ6" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Total deferred taxes net of valuation allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

13838000

12872000

1555000

32000

-270000

-33000

12013000

12807000

66000000

0.21

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 34px">8.</td> <td style="text-align: justify">Common Stock </td></tr> </table> Year Ending December 31, 2025 During the year ended December 31, 2025, the Company issued an aggregate of 114,925,716 shares of its common stock as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px; text-align: justify">·</td> <td style="text-align: justify">The Company issued <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250101__20251231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__us-gaap--ConvertibleNotesPayableMember_zOaBjakL3sD9" title="Debt converted, shares issued">65,523,469 shares of its common stock upon the conversion of $<span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20250101__20251231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__us-gaap--ConvertibleNotesPayableMember_z9r73xEPteia" title="Debt converted, amount converted">3,344,000 in convertible notes and $606,000 of accrued interest, net of unamortized discount of $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_pp0p0_c20251231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__us-gaap--ConvertibleNotesPayableMember_zkpFREIoebIb" title="Unamortized discount">1,572,000, pursuant to convertible notes conversion prices of $<span id="xdx_908_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20250101__20251231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__us-gaap--ConvertibleNotesPayableMember__srt--RangeAxis__srt--MinimumMember_zpa4XdURL5Ud" title="Conversion price">0.02 to $<span id="xdx_901_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20250101__20251231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__us-gaap--ConvertibleNotesPayableMember__srt--RangeAxis__srt--MaximumMember_zz82id6nHuVb" title="Conversion price">0.15 per share.</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">The Company issued <span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250101__20251231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--ExerciseOfOptionsAndWarrantsMember_zfVXjDIoFiA9" title="Debt converted, shares issued">36,802,254 shares of its common stock upon the exercise of options and warrants at $<span id="xdx_902_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20250101__20251231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--ExerciseOfOptionsAndWarrantsMember__srt--RangeAxis__srt--MinimumMember_zB6MaQGVV9Rc" title="Conversion price">0.02 to $<span id="xdx_90E_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20250101__20251231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--ExerciseOfOptionsAndWarrantsMember__srt--RangeAxis__srt--MaximumMember_zd6lRJF74gjk" title="Conversion price">0.15 per share, for total proceeds of $<span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20250101__20251231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--ExerciseOfOptionsAndWarrantsMember_zQzVPlyUwn68" title="Debt converted, amount converted">1,603,000.</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">The Company issued <span id="xdx_908_eus-gaap--ConversionOfStockSharesIssued1_c20250101__20251231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--CashlessExerciseOfWarrantsMember_zzXz0GW5ib1h" title="Stock converted, shares issued">2,049,993 shares of its common stock upon the cashless exercise of warrants at $<span id="xdx_903_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20250101__20251231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--CashlessExerciseOfWarrantsMember__srt--RangeAxis__srt--MinimumMember_zjqpNN5RHvJ5" title="Conversion price">0.03 to $<span id="xdx_909_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20250101__20251231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--CashlessExerciseOfWarrantsMember__srt--RangeAxis__srt--MaximumMember_zDn8i00zQRAf" title="Conversion price">0.15 per share for $<span id="xdx_90C_eus-gaap--ConversionOfStockAmountConverted1_c20250101__20251231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--CashlessExerciseOfWarrantsMember_z5utnOd0GVQb" title="Stock converted, amount converted">104,000, which were applied to the settlement of vendor payables.</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">The Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zA9KZpflQbxc" title="Stock shares issued for services">9,050,000 shares of its common stock for services of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zlnS1fZXApo5" title="Stock issued for services, value">1,451,000 valued at $0.04 to $0.19 per share based on the closing price of the Company’s common stock on the dates granted.</td></tr> </table> Year Ending December 31, 2024 During the year ended December 31, 2024, the Company issued an aggregate of 35,838,409 shares of its common stock as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px; text-align: justify">·</td> <td style="text-align: justify">The Company issued <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240101__20241231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__us-gaap--ConvertibleNotesPayableMember_zQ4I2d9M8xhb" title="Debt converted, shares issued">32,341,748 shares of its common stock upon the conversion of $<span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20240101__20241231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__us-gaap--ConvertibleNotesPayableMember_z9T4wQSqbTSh" title="Debt converted, amount converted">1,034,000 in convertible notes, net of unamortized discount of $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20241231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__us-gaap--ConvertibleNotesPayableMember_zo7M5kNEE9ac" title="Unamortized discount">698,000, pursuant to convertible notes conversion prices of $<span id="xdx_90E_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20240101__20241231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__us-gaap--ConvertibleNotesPayableMember__srt--RangeAxis__srt--MinimumMember_zhy0ZNt17UUb" title="Conversion price">0.03 to $<span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20240101__20241231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__us-gaap--ConvertibleNotesPayableMember__srt--RangeAxis__srt--MaximumMember_zllcu8pe5Gta" title="Conversion price">0.05 per share.</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">The Company issued <span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240101__20241231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--ExerciseOfWarrantsMember_zfZ6PhJGSJM6" title="Debt converted, shares issued">1,063,332 shares of its common stock upon the exercise of warrants at $<span id="xdx_90B_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20240101__20241231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--ExerciseOfWarrantsMember__srt--RangeAxis__srt--MinimumMember_zxXiro8aoxZb" title="Conversion price">0.04 to $<span id="xdx_909_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20240101__20241231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--ExerciseOfWarrantsMember__srt--RangeAxis__srt--MaximumMember_zv91LqAnwGPb" title="Conversion price">0.07 per share, for total proceeds of $<span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20240101__20241231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--ExerciseOfWarrantsMember_zEJFY5l44qp2" title="Debt converted, amount converted">52,000.</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">The Company issued <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240101__20241231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--CashlessExerciseOfWarrantsMember_zs5A9w93GQ65" title="Debt converted, shares issued">433,329 shares of its common stock upon the cashless exercise of warrants at $<span id="xdx_909_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20240101__20241231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--CashlessExerciseOfWarrantsMember__srt--RangeAxis__srt--MinimumMember_zFgRDzccWM9e" title="Conversion price">0.02 to $<span id="xdx_904_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20240101__20241231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--CashlessExerciseOfWarrantsMember__srt--RangeAxis__srt--MaximumMember_zro0YDE7brv6" title="Conversion price">0.06 per share for $<span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20240101__20241231__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--CashlessExerciseOfWarrantsMember_zPG1T5aV3M07" title="Debt converted, amount converted">18,000, which were applied to the settlement of accounts payable.</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">The Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zcOO1EGI4yR7" title="Stock shares issued for services">2,000,000 shares of its common stock upon services with a fair value of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zmD1bPPtpUqb" title="Stock issued for services, value">140,000, at $0.07 per share.</td></tr> </table>

114925716

65523469

3344000

606000

1572000

0.02

0.15

36802254

0.02

0.15

1603000

2049993

0.03

0.15

104000

9050000

1451000

0.04

0.19

35838409

32341748

1034000

698000

0.03

0.05

1063332

0.04

0.07

52000

433329

0.02

0.06

18000

2000000

140000

0.07

<p id="xdx_809_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zqLG7b5Aatnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 34px">9.</td> <td style="text-align: justify">Stock Options and Warrants</td></tr> </table> The Company periodically issues stock options and warrants to employees and non-employees in capital raising transactions, for services and for financing costs. Options and warrants vest and expire according to terms established at the grant date. Options Employee options vest according to the terms of the specific grant and expire from 5 to 10 years from date of grant. The weighted average, remaining contractual life of employee and non-employee options outstanding at December 31, 2025 was 6.6 years. Stock option activity for the period January 1, 2024 to December 31, 2025, was as follows: <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zeN6XbwWBZhf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Options and Warrants (Details - Options activity)"> <tr style="vertical-align: bottom"> <td>Schedule of stock option activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Options outstanding, December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdXdO2QVsqCl" style="width: 13%; text-align: right" title="Options, Beginning balance">25,757,155</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYkdudl7UG72" style="width: 13%; text-align: right" title="Weighted average exercise price, Beginning balance">0.14</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrZNZA48Za1c" style="text-align: right" title="Options, Granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDgJxtiwrAMd" style="text-align: right" title="Weighted average exercise price, Granted">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfBPz99wRri9" style="text-align: right" title="Options, Exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zuPifVMgpLdj" style="text-align: right" title="Weighted average exercise price, Exercised">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Options cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zA4nkBLxtHF8" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Expired">(463,052</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7ewfYImgZt" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired">0.85</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Options outstanding, December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZ90pI7tBg4d" style="text-align: right" title="Options, Beginning balance">25,294,103</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrENvyqQnde3" style="text-align: right" title="Weighted average exercise price, Beginning balance">0.13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4vlRW4XEVp9" style="text-align: right" title="Options, Granted">53,100,138</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxGBjGW17xQd" style="text-align: right" title="Weighted average exercise price, Granted">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJOEmSRXM4Ah" style="text-align: right" title="Options, Exercised">(8,640,688</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqEa1aR93BU7" style="text-align: right" title="Weighted average exercise price, Exercised">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Options cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2fS2EH2Ec6i" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Expired">(738,552</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zLfBTJg0w1ve" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired">0.48</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Options outstanding, December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMdmv24W4fK1" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Ending balance">69,015,001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zGVPrHffyyr6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Ending balance">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The weighted average exercise prices, remaining contractual lives for options granted, exercisable, and expected to vest as of December 31, 2025, were as follows: <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_ziJiyvmLnKvd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Options and Warrants (Details - Options by exercise price per share)"> <tr style="vertical-align: bottom"> <td>Schedule of weighted average exercise prices, remaining contractual lives for options granted, exercisable, and expected to vest</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Outstanding Options</td> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Exercisable Options</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid"> Option Exercise Price Per Share</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Life (Years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 30%; text-align: center">$0.02 - $0.24</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zOBwnz718cjg" style="width: 11%; text-align: right" title="Shares, options outstanding">66,515,001</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: center"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z1994CUifMlk" title="Life (Years), options outstanding">6.8</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z5wnEbgShR6g" style="width: 11%; text-align: right" title="Weighted average exercise price, options outstanding">0.06</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zdfY0xQk4QFd" style="width: 11%; text-align: right" title="Shares, options exercisable">66,515,001</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zHTaz1JCRYj3" style="width: 11%; text-align: right" title="Weighted average exercise price, options exercisable">0.06</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center">$0.25 - $0.49</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zMJ6dCYrcwNd" style="border-bottom: black 1pt solid; text-align: right" title="Shares, options outstanding">2,500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zex7FIkSrGqj" title="Life (Years), options outstanding">1.2</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zVj7OCSfIbS4" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, options outstanding">0.33</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z6HgyGti6D3h" style="border-bottom: black 1pt solid; text-align: right" title="Shares, options exercisable">2,500,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zIsd6p8pdjSb" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, options exercisable">0.33</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="text-align: center"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzgkaumjp8wk" style="border-bottom: black 2.25pt double; text-align: right" title="Shares, options outstanding">69,015,001</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQFx7Rrel0Jh" title="Life (Years), options outstanding">6.6</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7FeGQrFZmB6" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, options outstanding">0.07</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zalGXBPYTNrj" style="border-bottom: black 2.25pt double; text-align: right" title="Shares, options exercisable">69,015,001 </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7xy0fHU2Vne" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, options exercisable">0.07</td> <td> </td></tr> </table> As of December 31, 2025, the market price of the Company’s stock was $0.15 per share. At December 31, 2025 the aggregate intrinsic value of the options outstanding was $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zD9E2QsDWBXh" title="Aggregate intrinsic value of options outstanding">6,051,073. Options granted during 2025 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">·</td> <td style="text-align: justify">In January and February 2025, the Company issued options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20250131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zMDUrbC9aNs3" title="Options granted, shares"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250201__20250228__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zyysJ42r3S0k" title="Options granted, shares">17,482,638 shares of common stock to members of the Board of Directors, including <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20250131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--CecilBondKyteMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zAcrJ3BYG5sl"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250201__20250228__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--CecilBondKyteMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zxTJSF8s6XM8">7,218,750 options issued to the Company’s CEO/CFO upon reinstatement of the Director Compensation Policy. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price02Member_zUBqv4Ke2mCa" title="Options exercisable, shares">7,656,250 options are exercisable at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price02Member_zGG2UAJp1Wpl" title="Options exercisable, price per share">0.02 per share, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price04Member_zcDhM1l2suWg" title="Options exercisable, shares">4,375,000 options are exercisable at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price04Member_zp4JOZg7XfB1">0.04 per share, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price06Member_zOpf8OeFrWk2" title="Options exercisable, shares">2,430,555 options are exercisable at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price06Member_zcgxxplTmkc6">0.06 per share, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price08Member_zx6eJXBA8wL6" title="Options exercisable, shares">2,187,500 options are exercisable at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price08Member_zCg7BG4MDeKa">0.08 per share, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price15Member_zJZIZ0BxMOmi" title="Options exercisable, shares">833,333 options are exercisable at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price15Member_zyCaoEP4hG71">0.15 per share. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zbfa7Wzpa3Od" title="Options vested, shares">16,649,305 of the options were fully vested at the date of grant and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zUdvcidfFiDc" title="Options to be vested, shares">833,333 of the options vest through December 31, 2025. Total fair value of these options at grant date was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodValue_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zoQmO7SRvZ12" title="Options granted, fair value">2,571,000 using the Black-Scholes Option Pricing model with the following assumptions: expected life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zQniSvcKmL9h" title="Assumptions used - expected term">5 to 6 years; risk free interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zhskNtWoCx06" title="Assumptions used - risk free interest rate">4.47% to 4.57%; volatility of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zD88oQ1Cwz3i" title="Assumptions used - volatility rate, minimum">203% to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zVjqKe9fMQ0g" title="Assumptions used - volatility rate, maximum">205%, and dividend yield of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zDTc1N4fhb11" title="Assumptions used - dividend rate">0%. During the year ended December 31, 2025, the Company recognized compensation costs based on the fair value of options that vested of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_908_eus-gaap--ShareBasedCompensation_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zpKTxR7e967e" title="Share based compensation expense">2,571,000.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td style="text-align: justify">In January 2025, the Company issued options to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20250131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CecilBondKyteMember_zvt50YTOJgfb" title="Options granted, shares">24,317,500 shares of common stock upon execution of an employment agreement with Mr. Cecil Bond Kyte, the Company’s CEO/CFO. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CecilBondKyteMember_zrX8mgM3Gai6" title="Options exercisable">20,817,500 options are exercisable at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20250131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CecilBondKyteMember_zcIjQLvA5WMe" title="Exercise price">0.03 per share, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisablesNumber_iI_c20250131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CecilBondKyteMember_zHU9JvcWTDNb" title="Options exercisables">3,500,000 options are exercisable at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisesPrice_iI_c20250131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CecilBondKyteMember_zxnLImvy3Zt3" title="Exercise price per share">0.15 per share, The options are fully vested at the date of grant, and expire in <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CecilBondKyteMember_zKEXPE4lRU1l" title="Options, contractural term">10 years. Total fair value of these options at grant date was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodValue_c20250101__20250131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CecilBondKyteMember_zy9wKq8VUby3">3,614,000 using the Black-Scholes Option Pricing model with the following assumptions: expected life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CecilBondKyteMember_zeN7b3HEB4M5" title="Options granted - expected term">5 years; risk free interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250101__20250131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CecilBondKyteMember_z0LzNlEaLqNb" title="Options granted - risk-free interest rate">4.57%; volatility of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250101__20250131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CecilBondKyteMember_z1YVOlP0dYeh" title="Assumptions used - volatility rate">207% and dividend yield of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250101__20250131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CecilBondKyteMember_z9aU8kKcPkYk" title="Assumptions used - dividend rate">0%. During the year ended December 31, 2025, the Company recognized compensation costs based on the fair value of options that vested of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_907_eus-gaap--ShareBasedCompensation_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CecilBondKyteMember_zjtpbbbw7iBj" title="Share based compensation">3,614,000.</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td> In March 2025, the Company issued options to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250301__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember_zPwHFiWjcZwe" title="Options granted, shares">1,500,000 shares of common stock to its corporate secretary as compensation. The options are exercisable at a price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember_zA4duxkHPINf">0.03, one third of the options vested immediately, one third of the options vest in one year, and one third vest in two years. The options expire in <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250301__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember_zjxBcjDCOFr3">10 years. Total fair value of these options at grant date was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodValue_c20250301__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember_zdZdoBZWk7Lj">238,000 using the Black-Scholes Option Pricing model with the following assumptions: expected life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250301__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember_zp0xt0NqtKQf">6 years; risk free interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250301__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember_z4BuEnUfG96b">4.32%; volatility of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250301__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember_zil04RAFi6Hk">179% and dividend yield of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250301__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember_zv5QfXjOBCSg">0%. During the year ended December 31, 2025, the Company recognized compensation costs based on the fair value of options that vested of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_901_eus-gaap--ShareBasedCompensation_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--CounterpartyNameAxis__custom--CorporateSecretaryMember_zPo2dDwr0iq3" title="Compensation costs">143,000. </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">·</td> <td> During 2025, the Company issued options to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember_z9x7Mt2zxfsg" title="Options granted, shares">9,800,000 shares of common stock in exchange for services. The options are exercisable at a price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember_znnQ0BU8Z3Se">0.03, vest up to two years from the date of grant, and expire <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember__srt--RangeAxis__srt--MinimumMember_zjVf3qNxVXc5" title="Expire year">5 to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember__srt--RangeAxis__srt--MaximumMember_zv73029P4IR9">10 years from the date of grant. Total fair value of these options at grant date was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodValue_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember_zetHkHL3pnD" title="Fair value of options grant">1,575,000 using the Black-Scholes Option Pricing model with the following assumptions: life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember__srt--RangeAxis__srt--MinimumMember_zmTM4EmKncD6">2.5 to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember__srt--RangeAxis__srt--MaximumMember_z80OgOeCxzxi">6 years; risk free interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember__srt--RangeAxis__srt--MinimumMember_zoqhGUHFcmxc" title="Assumptions used - risk free interest rate">3.92% to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember__srt--RangeAxis__srt--MaximumMember_zo5YSwNowXfl" title="Assumptions used - risk free interest rate">4.32%; volatility of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember__srt--RangeAxis__srt--MinimumMember_z3vIziWqjo92" title="Assumptions used - volatility rate">179% to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember__srt--RangeAxis__srt--MaximumMember_zig2yYZs5Ikf" title="Assumptions used - volatility rate">201% and dividend yield of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember_z2YEa3V68Lok" title="Assumptions used - dividend rate">0%. During the year ended December 31, 2025, the Company recognized compensation costs based on the fair value of options that vested of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_901_eus-gaap--ShareBasedCompensation_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--TransactionTypeAxis__custom--IssuedForServicesMember_zv1bqBIsGaB6" title="Compensation costs">1,020,000. </td></tr> </table> Options granted in 2024 During the year ended December 31, 2024, the Company did not issue any options. Warrants The following table summarizes certain information about the Company’s stock purchase warrants. <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zUNLTCJz7c0c" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Options and Warrants (Details - Warrants activity)"> <tr style="vertical-align: bottom"> <td>Schedule of warrants activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Warrants outstanding, December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zijxlE81yUbf" style="width: 13%; text-align: right" title="Warrants, beginning balance">17,953,239</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRVxcVMT32K4" style="width: 13%; text-align: right" title="Weighted average exercise price, beginning balance">0.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1v7JPwJ7t6l" style="text-align: right" title="Warrants granted">44,340,676</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwUYGeJe1Lxl" style="text-align: right" title="Weighted average exercise price, Granted">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPXYgOABBWyl" style="text-align: right" title="Warrants exercised">(1,496,661</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ze6SZiUpdNJ1" style="text-align: right" title="Weighted average exercise price, Exercised">0.05</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zXXdfol1LPCl" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Expired">(16,753,245</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zXVZeHLuVGN6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired">0.06</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Warrants outstanding, December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zggy1AveGUT8" style="text-align: right" title="Warrants, beginning balance">44,044,009</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUINcMi5eDK2" style="text-align: right" title="Weighted average exercise price, beginning balance">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSV89qLEyu49" style="text-align: right" title="Warrants granted">31,823,611</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9UFhWbBGGV2" style="text-align: right" title="Weighted average exercise price, Granted">0.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zuJKv0pC4mp4" style="text-align: right" title="Warrants exercised">(30,211,559</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zyNas4rFYfgh" style="text-align: right" title="Weighted average exercise price, Exercised">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zCHCZgwGLa9k" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Expired">(33,333</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zM6DqgCsc2mb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired">0.13</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Warrants outstanding, December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1dq39oCc3bi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, ending balance">45,622,728</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zTIlr80XvRUe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance">0.08</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> At December 31, 2025 the price of the Company’s common stock was $0.15 per share and the aggregate intrinsic value of the warrants outstanding was $<span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zndyu1OgIoO" title="Intrinsic value">3,091,990. As of December 31, 2025, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjXedgQ3Fvlh" title="Warrants fully vested">45,589,395 warrants were fully vested and <span id="xdx_906_ecustom--WarrantsExpectedToVest_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zETmRU89dqFa" title="Warrants vest">33,333 warrants vest in January 2026. <table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockWarrantPlansByExercisePriceRangeTextBlock_z7kCb2fwbcEf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Options and Warrants (Details - Warrants exercise price per share)"> <tr style="vertical-align: bottom"> <td>Schedule of weighted average exercise prices, remaining contractual lives for warrants granted, exercisable, and expected to vest</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="9" style="border-bottom: black 1pt solid; text-align: center">Outstanding Warrants</td> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Exercisable Warrants</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid"> Option Exercise Price Per Share</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center">Life (Years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 31%; text-align: center">$0.02 - $0.24</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant1Member_zMlq8nupnAKl" style="width: 11%; text-align: right">45,489,396</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: center"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price1Member_zX8BWWub9uUi" title="Life (Years), warrants outstanding">0.6</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant1Member_zO6rHJEP8lra" style="width: 11%; text-align: right">0.08</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant1Member_zF5eTZ1s2wbl" style="width: 11%; text-align: right">45,456,063</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant1Member_zJd5Z9MxZRa9" style="width: 11%; text-align: right">0.08</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center">$0.25 - $0.49</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant2Member_z4aH39ehUQib" style="border-bottom: black 1pt solid; text-align: right" title="Warrants outstanding">133,332</td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price2Member_zWfDBbZvSzX5" title="Life (Years), warrants outstanding">1.6</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant2Member_zuCUXdkPVfqf" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, warrants outstanding">0.28</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_d0_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant2Member_zDWZRxKd50J6" style="border-bottom: black 1pt solid; text-align: right" title="Warrants exercisable">133,332</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_d0_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant2Member_z9v2zfpNGsH2" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, warrants exercisable">0.28</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="text-align: center"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zbD7NDNAG7xg" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants outstanding">45,622,728</td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqjWmD1b10qk" title="Life (Years), warrants outstanding">0.6</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdBrjrV6rlhe" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, warrants outstanding">0.08</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zU1VVlD5Wp2b" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants exercisable">45,589,395</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zuY7KujOIzE3" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, warrants exercisable">0.08</td> <td> </td></tr> </table> Warrants granted in 2025 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">·</td> <td style="text-align: justify">During 2025, pursuant to terms of convertible notes issued, the Company granted warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zFX3Uk19mlXe" title="Warrants granted">31,423,615 shares of common stock with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zNFRUYybOla8" title="Exercise price">0.10 per share, vesting immediately upon grant and expiring one year from the date of grant.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify">During 2025, pursuant to terms of consulting agreements, the Company granted warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_z3vQybb0FsVc" title="Warrants granted">399,996 shares of common stock with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember__srt--RangeAxis__srt--MinimumMember_zbmwJ1WR0ue8" title="Share based compensation exercise price range">0.14 to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember__srt--RangeAxis__srt--MaximumMember_zLOKOqjKdpVe" title="Share based compensation exercise price range">0.30 per share, vesting one month from the date of grant and expiring in two years. Total fair value of these options at grant date was approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_908_ecustom--FairValueOfWarrantsGranted_pp0p0_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_zg2jSYdWHWo2" title="Fair value of warrants granted">60,000 determined using the Black-Scholes Option Pricing model with the following assumptions: life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_zKUGefiAusE5" title="Expected life">2 years; risk free interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_z1xerubyuud4" title="Risk free interest rate - minimum">3.57% to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_zN5qvk97OObi" title="Risk free interest rate - maximum">4.82%; volatility of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_zYte5I7z4ZC" title="Volatility - minimum">147% to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_zVaUWwL5Frg6" title="Volatility - maximum">158% and dividend yield of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_z3eI4gnSYBLk" title="Expected dividend yield">0%. During the year ended December 31, 2025, the Company recognized compensation expense of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0p0_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_zhhzdMGLrfah" title="Share based compensation expense">59,000 based on the fair value of the warrants that vested.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify">During 2025, the Company extended the expiration date of warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForConsultantsAndInvestorsMember_zEt7IYHWlZo3" title="Warrants granted">13,796,200 shares of common stock. The warrants had been issued to certain consultants and certain investors, and the modifications were executed to compensate the warrant holders for services provided. The Company measured the fair value of the modified warrants as of the modification date and compared it to the fair value of the warrants immediately before modification. The incremental fair value resulting from the modification was determined to be $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_902_ecustom--FairValueOfWarrantsGranted_pp0p0_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForConsultantsAndInvestorsMember_zrgr2PTeby3e">511,000 using a Black-Scholes Option Pricing model with the following assumptions: life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForConsultantsAndInvestorsMember__srt--RangeAxis__srt--MinimumMember_zPLIlnWYWAdk">1 to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForConsultantsAndInvestorsMember__srt--RangeAxis__srt--MaximumMember_zW43Q88wc3s2">2 years; risk free interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForConsultantsAndInvestorsMember_zzlYtXzrPbS1">3.94% to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForConsultantsAndInvestorsMember_zG684j9UChdg">4.31%; volatility of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForConsultantsAndInvestorsMember_zLEDoR7PIxYj">133% to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForConsultantsAndInvestorsMember_zlIDMy111v1k">154% and dividend yield of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForConsultantsAndInvestorsMember_zDOb4ztqMGZ4">0%. The warrants were fully vested on the modification date, and the full incremental fair value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_906_eus-gaap--ShareBasedCompensation_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--WarrantsIssuedForConsultantsAndInvestorsMember_ze0eTH4vOYEf">511,000 was recognized as stock-based compensation - warrant modification.</td></tr> </table> Warrants granted in 2024 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">·</td> <td style="text-align: justify">During 2024, pursuant to terms of convertible notes issued, the Company granted warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zvfAU9XD88Jc" title="Warrants granted">42,457,348 shares of common stock with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__srt--RangeAxis__srt--MinimumMember_ztf2z98zc0f2" title="Exercise price">0.04 to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__srt--RangeAxis__srt--MaximumMember_zrhGCgtw5fVc" title="Exercise price">0.07 per share, vesting immediately upon grant and expiring one year from the date of grant.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify">During 2024, pursuant to terms of consulting agreements, the Company granted warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_zBosy9p8Kl53" title="Warrants granted">1,883,328 shares of common stock with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember__srt--RangeAxis__srt--MinimumMember_zjQeYAUDLik7" title="Share based compensation exercise price range">0.03 to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember__srt--RangeAxis__srt--MaximumMember_zFO1V3CFZGrc" title="Share based compensation exercise price range">0.15 per share, vesting up to one month from the date of grant and expiring one to two years from the date of grant. Total fair value of these options at grant date was approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_908_ecustom--FairValueOfWarrantsGranted_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_zfw1RqjT6Hb2" title="Fair value of warrants granted">152,000 determined using the Black-Scholes Option Pricing model with the following assumptions: life of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember__srt--RangeAxis__srt--MinimumMember_zvZY6jZve0Ia" title="Expected life">1 to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember__srt--RangeAxis__srt--MaximumMember_zpssYBZ7ZUW1" title="Expected life">2 years; risk free interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_zX9FKtUaPI94" title="Risk free interest rate - minimum">3.55% to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_zU7LxWDZ8Uu" title="Risk free interest rate - maximum">4.97%; volatility of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_zRZs5OBLMrG1" title="Volatility - minimum">167% to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_zrEmECXuQCx2" title="Volatility - maximum">188% and dividend yield of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_zWpByT0tV5g8" title="Expected dividend yield">0%. During the year ended December 31, 2024, the Company recognized compensation expense of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN0b2NrIE9wdGlvbnMgYW5kIFdhcnJhbnRzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--TransactionTypeAxis__custom--ConsultingAgreementMember_zbev5JQAeiye" title="Share based compensation expense">150,000 based on the fair value of the warrants that vested.</td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zeN6XbwWBZhf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Options and Warrants (Details - Options activity)"> <tr style="vertical-align: bottom"> <td>Schedule of stock option activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Options outstanding, December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdXdO2QVsqCl" style="width: 13%; text-align: right" title="Options, Beginning balance">25,757,155</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYkdudl7UG72" style="width: 13%; text-align: right" title="Weighted average exercise price, Beginning balance">0.14</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrZNZA48Za1c" style="text-align: right" title="Options, Granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDgJxtiwrAMd" style="text-align: right" title="Weighted average exercise price, Granted">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfBPz99wRri9" style="text-align: right" title="Options, Exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zuPifVMgpLdj" style="text-align: right" title="Weighted average exercise price, Exercised">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Options cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zA4nkBLxtHF8" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Expired">(463,052</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7ewfYImgZt" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired">0.85</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Options outstanding, December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZ90pI7tBg4d" style="text-align: right" title="Options, Beginning balance">25,294,103</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrENvyqQnde3" style="text-align: right" title="Weighted average exercise price, Beginning balance">0.13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4vlRW4XEVp9" style="text-align: right" title="Options, Granted">53,100,138</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxGBjGW17xQd" style="text-align: right" title="Weighted average exercise price, Granted">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJOEmSRXM4Ah" style="text-align: right" title="Options, Exercised">(8,640,688</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqEa1aR93BU7" style="text-align: right" title="Weighted average exercise price, Exercised">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Options cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2fS2EH2Ec6i" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Expired">(738,552</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zLfBTJg0w1ve" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired">0.48</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Options outstanding, December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMdmv24W4fK1" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Ending balance">69,015,001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zGVPrHffyyr6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Ending balance">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

25757155

0.14

-0

463052

0.85

25294103

0.13

53100138

0.04

8640688

0.04

738552

0.48

69015001

0.07

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_ziJiyvmLnKvd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Options and Warrants (Details - Options by exercise price per share)"> <tr style="vertical-align: bottom"> <td>Schedule of weighted average exercise prices, remaining contractual lives for options granted, exercisable, and expected to vest</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Outstanding Options</td> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Exercisable Options</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid"> Option Exercise Price Per Share</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Life (Years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 30%; text-align: center">$0.02 - $0.24</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zOBwnz718cjg" style="width: 11%; text-align: right" title="Shares, options outstanding">66,515,001</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: center"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z1994CUifMlk" title="Life (Years), options outstanding">6.8</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z5wnEbgShR6g" style="width: 11%; text-align: right" title="Weighted average exercise price, options outstanding">0.06</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zdfY0xQk4QFd" style="width: 11%; text-align: right" title="Shares, options exercisable">66,515,001</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zHTaz1JCRYj3" style="width: 11%; text-align: right" title="Weighted average exercise price, options exercisable">0.06</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center">$0.25 - $0.49</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zMJ6dCYrcwNd" style="border-bottom: black 1pt solid; text-align: right" title="Shares, options outstanding">2,500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zex7FIkSrGqj" title="Life (Years), options outstanding">1.2</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zVj7OCSfIbS4" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, options outstanding">0.33</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z6HgyGti6D3h" style="border-bottom: black 1pt solid; text-align: right" title="Shares, options exercisable">2,500,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zIsd6p8pdjSb" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, options exercisable">0.33</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="text-align: center"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzgkaumjp8wk" style="border-bottom: black 2.25pt double; text-align: right" title="Shares, options outstanding">69,015,001</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQFx7Rrel0Jh" title="Life (Years), options outstanding">6.6</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7FeGQrFZmB6" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, options outstanding">0.07</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zalGXBPYTNrj" style="border-bottom: black 2.25pt double; text-align: right" title="Shares, options exercisable">69,015,001 </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7xy0fHU2Vne" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, options exercisable">0.07</td> <td> </td></tr> </table>

66515001

P6Y9M18D

0.06

66515001

0.06

2500000

P1Y2M12D

0.33

2500000

0.33

69015001

P6Y7M6D

0.07

69015001

0.07

0.15

6051073

17482638

7218750

7656250

0.02

4375000

0.04

2430555

0.06

2187500

0.08

833333

0.15

16649305

833333

2571000

5 to 6 years

4.47% to 4.57%

2.03

2.05

2571000

24317500

20817500

0.03

3500000 0.15

P10Y

3614000

P5Y

0.0457

2.07

3614000

1500000

0.03

P10Y

238000

P6Y

0.0432

1.79

143000

9800000

0.03

P5Y

P10Y

1575000

P2Y6M

P6Y

0.0392

0.0432

1.79

2.01

1020000

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zUNLTCJz7c0c" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Options and Warrants (Details - Warrants activity)"> <tr style="vertical-align: bottom"> <td>Schedule of warrants activity</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Warrants outstanding, December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zijxlE81yUbf" style="width: 13%; text-align: right" title="Warrants, beginning balance">17,953,239</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRVxcVMT32K4" style="width: 13%; text-align: right" title="Weighted average exercise price, beginning balance">0.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1v7JPwJ7t6l" style="text-align: right" title="Warrants granted">44,340,676</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwUYGeJe1Lxl" style="text-align: right" title="Weighted average exercise price, Granted">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPXYgOABBWyl" style="text-align: right" title="Warrants exercised">(1,496,661</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ze6SZiUpdNJ1" style="text-align: right" title="Weighted average exercise price, Exercised">0.05</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zXXdfol1LPCl" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Expired">(16,753,245</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zXVZeHLuVGN6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired">0.06</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Warrants outstanding, December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zggy1AveGUT8" style="text-align: right" title="Warrants, beginning balance">44,044,009</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUINcMi5eDK2" style="text-align: right" title="Weighted average exercise price, beginning balance">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSV89qLEyu49" style="text-align: right" title="Warrants granted">31,823,611</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9UFhWbBGGV2" style="text-align: right" title="Weighted average exercise price, Granted">0.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zuJKv0pC4mp4" style="text-align: right" title="Warrants exercised">(30,211,559</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zyNas4rFYfgh" style="text-align: right" title="Weighted average exercise price, Exercised">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zCHCZgwGLa9k" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Expired">(33,333</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zM6DqgCsc2mb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired">0.13</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Warrants outstanding, December 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1dq39oCc3bi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, ending balance">45,622,728</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zTIlr80XvRUe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance">0.08</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

17953239

0.06

44340676

0.04

1496661

0.05

16753245

0.06

44044009

0.04

31823611

0.10

30211559

0.04

33333

0.13

45622728

0.08

0.15

3091990

45589395

33333 <table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockWarrantPlansByExercisePriceRangeTextBlock_z7kCb2fwbcEf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Options and Warrants (Details - Warrants exercise price per share)"> <tr style="vertical-align: bottom"> <td>Schedule of weighted average exercise prices, remaining contractual lives for warrants granted, exercisable, and expected to vest</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="9" style="border-bottom: black 1pt solid; text-align: center">Outstanding Warrants</td> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Exercisable Warrants</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid"> Option Exercise Price Per Share</td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; text-align: center">Life (Years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="width: 31%; text-align: center">$0.02 - $0.24</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant1Member_zMlq8nupnAKl" style="width: 11%; text-align: right">45,489,396</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: center"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price1Member_zX8BWWub9uUi" title="Life (Years), warrants outstanding">0.6</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant1Member_zO6rHJEP8lra" style="width: 11%; text-align: right">0.08</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant1Member_zF5eTZ1s2wbl" style="width: 11%; text-align: right">45,456,063</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant1Member_zJd5Z9MxZRa9" style="width: 11%; text-align: right">0.08</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center">$0.25 - $0.49</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant2Member_z4aH39ehUQib" style="border-bottom: black 1pt solid; text-align: right" title="Warrants outstanding">133,332</td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price2Member_zWfDBbZvSzX5" title="Life (Years), warrants outstanding">1.6</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant2Member_zuCUXdkPVfqf" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, warrants outstanding">0.28</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_d0_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant2Member_zDWZRxKd50J6" style="border-bottom: black 1pt solid; text-align: right" title="Warrants exercisable">133,332</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_d0_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Warrant2Member_z9v2zfpNGsH2" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price, warrants exercisable">0.28</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #EEEEEE"> <td style="text-align: center"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zbD7NDNAG7xg" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants outstanding">45,622,728</td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqjWmD1b10qk" title="Life (Years), warrants outstanding">0.6</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdBrjrV6rlhe" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, warrants outstanding">0.08</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zU1VVlD5Wp2b" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants exercisable">45,589,395</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zuY7KujOIzE3" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price, warrants exercisable">0.08</td> <td> </td></tr> </table>

45489396

P0Y7M6D

0.08

45456063

0.08

133332

P1Y7M6D

0.28

133332

0.28

45622728

P0Y7M6D

0.08

45589395

0.08

31423615

0.10

399996

0.14

0.30

60000

P2Y

0.0357

0.0482

1.47

1.58

59000

13796200

511000

P1Y

P2Y

0.0394

0.0431

1.33

1.54

511000

42457348

0.04

0.07

1883328

0.03

0.15

152000

P1Y

P2Y

0.0355

0.0497

1.67

1.88

150000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 34px">10.</td> <td style="text-align: justify">Related Party Transactions</td></tr> </table> Employment Agreement with CEO/CFO Effective April 15, 2021, Cecil Bond Kyte was appointed to serve as the Company’s Chief Executive Officer and Chief Financial Officer upon mutually acceptable terms and conditions to be determined at a later date subject to the Company’s financial condition. From April 15, 2021 through July 7, 2024, Mr. Kyte served as the Company’s CEO and CFO without compensation. For the period July 7, 2024, through December 31, 2024, the Company paid Mr. Kyte $210,000 for his services as CEO and CFO of the Company. On February 19, 2025, effective January 1, 2025, the Company entered into an employment agreement (the “Employment Agreement”) with Mr. Kyte to serve as the Company’s CEO and CFO, with an annual base salary of $<span id="xdx_90C_ecustom--AnnualBaseSalary_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember_zk8ezAk03Gb" title="Annual base salary">420,000. In addition, the Employment Agreement provides for the payment of a retention bonus (“Bonus”) in the amount of $<span id="xdx_90D_ecustom--RetentionBonusPayable_iI_c20250102__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember_zAT7OpuQyxx1" title="Retention bonus payable">1,557,500 to Mr. Kyte, $<span id="xdx_90D_eus-gaap--LaborAndRelatedExpense_c20250101__20250131__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember_zmS9SJz6rV7g" title="Payment of retention bonus">519,167 of which was paid in January 2025 to Mr. Kyte on execution of the Employment Agreement; $519,167 of the Bonus was paid in part in May 2025 in anticipation of the execution of a customer contract with VIPS Petroleum, and the balance of that payment was paid in June and July 2025 to Mr. Kyte; and, $<span id="xdx_909_ecustom--RetentionBonusToBePaid_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember__us-gaap--TransactionTypeAxis__custom--ExecutionOfEquityFinancingMember_zaHyooHApq53" title="Retention bonus to be paid">519,166 of the Bonus will be paid to Mr. Kyte upon the execution, closing, and effective date of debt or equity financing in favor of the Company in the amount of no less than $5,000,000. As part of the Employment Agreement, Mr. Kyte was also issued a stock option exercisable into <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zOSL2nB7uDu6" title="Options granted, shares">20,817,500 shares of the Company’s restricted common stock at an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_z3k41vMp2NMd">0.03 per share, and a stock option exercisable into <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonStock2Member_zdsdlOqRfaQ2" title="Options granted, shares">3,500,000 shares of the Company’s restricted common stock at an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--CEOAndCFOMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonStock2Member_zSBgV8SZAlp2" title="Exercise price">0.03 per share. (See Note 9, above.) The stock options vested immediately and expire in ten years. Mr. Kyte was also issued stock options exercisable into <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__srt--CounterpartyNameAxis__custom--MembersOfTheBoardOfDirectorsMember_zSu1xiCIFFZ9">7,218,750 shares of the Company’s restricted stock in his capacity as a member of the Board of Directors and as a Chairman of the Board who oversees financial and audit functions, which vest up to one year, and have an exercise price of $0.02 to $0.15 per share. Accrued Expenses – Related Party As of December 31, 2025 and 2024, total accrued expenses – related parties amounted to $0 and $6,000 and are included in accrued expense on the accompanying consolidated balance sheet. The accrued expenses – related parties consist of unpaid board and committee fees to members of the Company’s Board of Directors. Reimbursements for Rent – Related Party The Company reimburses Cecil Bond Kyte, Company CEO and CFO, in rent expenses for a home office and partial storage space in Carson City, Nevada at a rate of $1,000 per month under a month-to-month rental agreement (“Carson Rental Agreement”). Total rent expense under the Carson Rental Agreement during the years ended December 31, 2025, and 2024 were $3,000 and $12,000, respectively which are included as part of Operating Expenses in the attached consolidated statement of operations.

210000

420000 1557500

519167

519166

20817500

0.03

3500000

0.03

7218750

0 6000

1000

3000

12000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 34px">11.</td> <td style="text-align: justify">Commitments and Contingencies</td></tr> </table> We are involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. There is no current or pending litigation of any significance with the exception of the matters that have arisen under, and are being handled in, the normal course of business. At December 31, 2025 and 2024, the Company has recorded $197,000 related to certain contractually provided benefits to a former executive officer pursuant to a severance agreement. The former executive officer disputes the amount of $197,000, claiming the amount is less than the amount to which he believes he is owed. Absent an agreement to settle the dispute, and in the event the former executive officer elects to initiate litigation regarding the dispute, including claims for interest and penalties to which the former executive officer believes he is entitled, the Company has reserved, and if necessary and appropriate will assert, all factual and legal defenses, counter-claims, rights, and remedies it may have in any such suit. The Company believes it has recorded an appropriate accrual for the matter. Significant Agreement In 2024, the Company entered into a Collaboration Agreement with VIPS Petroleum, LLC (“VIPS”) to collaborate with them in facilitating the deployment of our AOT technology and products to VIPS’ customers. On June 25, 2025, the Company entered into a Distributor Agreement with VIPS, providing for VIPS to serve as our exclusive distributor to promote, sell, and lease our AOT product in the territories of Malaysia, Ghana, and India, among other territories. To date, we have not received any purchase orders under the Distributor Agreement, nor has our AOT product been placed with, nor currently being used by, any of VIPS’ customers or anyone else. The Distributor Agreement, as amended, provides that upon the Company’s receipt of payment for the purchase of two AOT Units, the Company shall issue VIPS/Stephen Bosco a stock purchase warrant exercisable into 25,000,000 restricted shares of the Company’s common stock, at a price of $0.07 cents per share (the “Exercise Price”). The warrant will vest on issuance and expire three years from the date of issuance. VIPS’ payment of the Exercise Price shall be rebate-based, meaning, for every AOT Unit sold by the Company to VIPS, the Company will process a post-sale rebate of 15% of the purchase price to VIPS. Post-sale rebates due VIPS, up to a maximum of $1,750,000, will be applied to, and be deemed payment of, the Exercise Price. To date, we have not received any purchase orders, nor generated any revenue, under the Distributor Agreement, as amended, nor has our AOT product been placed with, nor is it currently being used by, any of VIPS’ customers or anyone else, and we can provide no assurances that our AOT product will be accepted or purchased by VIPS, or any of its customers, or anyone else. Subsequent to year-end the Company, together with VIPS and stakeholders identified under the VIPS Distributor Agreement, advanced the India commercialization pathway as reflected in the non-binding Laksel LOI. (See Note 13, below.)

197000

25000000

0.07

1750000

12. Segment information The Company operates and manages its business as one reportable and operating segment dedicated to biopharmaceutical research and development company specializing in oncology. The measure of segment assets is reported on the balance sheet as total consolidated assets. In addition, the Company manages the business activities on a consolidated basis. The Company’s CODM reviews financial information presented on a consolidated basis and decides how to allocate resources based on consolidated net income (loss). Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM: <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zAtfNexZhK16" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of significant segment expenses</td><td> </td> <td colspan="2" id="xdx_49C_20250101__20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zIQW8gCaQJCc" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_496_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zin4BMEwTOT5" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--Revenues_d0_zRs7exFxTovd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Revenue</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_iN_di_zUxW4j2sJPij" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">(1,611,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">(191,000</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--EmployeeBenefitPayrollAndRelated_iN_di_z4WF36eLSZH4" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Payroll and related</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,944,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(296,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_iN_di_zgw37tlJsdm" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,609,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(292,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_ecustom--ConsultingRelatedToIntellectualProperty_iN_di_zdN5c5bhCkLk" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Consulting related to intellectual property</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,072,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(439,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--InsuranceRecoveries_iN_di_zXPvYkV1tts8" style="vertical-align: bottom; background-color: White"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(159,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(77,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--OperatingExpenses_iN_di_zbVV1Wi46I8j" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(521,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(281,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--InterestExpenseOther_iN_di_zAiwTzcrQaS4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Interest expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(389,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(358,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLoss_z0TxpuVeZ6d4" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(15,305,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,934,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zAtfNexZhK16" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of significant segment expenses</td><td> </td> <td colspan="2" id="xdx_49C_20250101__20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zIQW8gCaQJCc" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_496_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zin4BMEwTOT5" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--Revenues_d0_zRs7exFxTovd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Revenue</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_iN_di_zUxW4j2sJPij" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">(1,611,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">(191,000</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--EmployeeBenefitPayrollAndRelated_iN_di_z4WF36eLSZH4" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Payroll and related</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,944,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(296,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_iN_di_zgw37tlJsdm" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,609,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(292,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_ecustom--ConsultingRelatedToIntellectualProperty_iN_di_zdN5c5bhCkLk" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Consulting related to intellectual property</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,072,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(439,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--InsuranceRecoveries_iN_di_zXPvYkV1tts8" style="vertical-align: bottom; background-color: White"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(159,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(77,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--OperatingExpenses_iN_di_zbVV1Wi46I8j" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(521,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(281,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--InterestExpenseOther_iN_di_zAiwTzcrQaS4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Interest expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(389,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(358,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLoss_z0TxpuVeZ6d4" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(15,305,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,934,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

1611000

191000

1944000 296000

9609000

292000

1072000 439000

159000

77000

521000

281000

389000

358000

-15305000

-1934000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">13.</td> <td>Subsequent Events </td></tr> </table> In January 2026, the Company issued 1,691,250 shares of its common stock upon the conversion of notes payable and accrued interest thereon at a conversion price of $0.08 per share. In January through March 2026, pursuant to terms of a consulting agreement, the Company granted warrants to purchase 99,999 shares of common stock with an exercise price of $0.09 to $0.10 per share, vesting one month from grant and expiring two years from the date of grant. In January through February 2026, the Company issued 4,718,188 shares of its common stock upon the exercise of warrants for proceeds of $472,000 at an exercise price of $0.10 per share. On March 30, 2026, as a continuation of the Company's previously disclosed collaboration and distribution arrangements with VIPS (see Note 11, above), the Company entered into a non-binding letter of intent with Laksel Corporation Pte Ltd ("Laksel") titled "Applied Oil Technology (AOT) India Deployment Program" (the "Laksel LOI") that contemplates the deployment of 150 units of the Company's Applied Oil Technology ("AOT"). The parties intend to establish a jointly held special purpose vehicle incorporated in India to serve as the primary operating entity for the program. The program is subject to the commitment of senior secured financing, negotiation and execution of definitive agreements among all parties, satisfaction of the conditions precedent set forth in such agreements, and receipt of required corporate, governmental, and regulatory approvals. The Laksel LOI is expressly non-binding, does not create any obligation on either party to proceed with the program or any related transaction, and may be terminated by either party in accordance with its terms. As of the date of this report, no revenues have been recognized and no amounts are payable under the Laksel LOI.